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Abstract
Many of the major milestones in understanding the olfactory system have arisen from research
conducted in non-human animal models through the use of various genetic tools. While mammalian
olfaction is largely conserved, there are several key differences in humans that suggest the necessity of
studies directed at human olfaction. The human olfactory system has both genotypic variation and
phenotypic variation, suggesting that, like in animal research, genetic tools are viable and vital for
investigating human olfaction. We first address the basic questions of the human olfactory system,
examining whether our assumptions based on animal olfaction are confirmed and attempting to identify
mechanisms of the olfactory system that are not well-characterized in humans or other animals. We
conducted whole exome sequencing on 52 individuals in ten families with congenital anosmia, an
inherited disorder where individuals lack a sense of smell from birth. Through selection of rare,
segregating, deleterious variants, we identified 215 genes that are associated with congenital anosmia.
These genes are likely to play a role in olfaction, and can therefore serve as a resource for further
investigation of the underlying mechanisms of basic human olfaction. We next investigated the
relationship between olfactory receptors and odor perception in order to improve our understanding of
how odor information is processed at the periphery. Here, we identified two novel associations: a variant
in OR51B2 that increases intensity perception of a key component of body odor, and two-linked variants in
OR4D6 that predict specific anosmia to the musk compound Galaxolide. Uncovering the relationship
between odors and their specific receptors is the first step to understanding how the ~400 olfactory
receptors work in combination to code for odor perception. These studies make advances towards a
comprehensive understanding of how the human peripheral olfactory system functions and codes
olfactory information into odor perception.
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ABSTRACT

HOW DO YOUR GENES SMELL?
APPLYING GENETIC TOOLS TO UNDERSTAND OLFACTORY PERCEPTION
Marissa L. Kamarck
Joel D. Mainland
Many of the major milestones in understanding the olfactory system have arisen from
research conducted in non-human animal models through the use of various genetic tools. While
mammalian olfaction is largely conserved, there are several key differences in humans that
suggest the necessity of studies directed at human olfaction. The human olfactory system has
both genotypic variation and phenotypic variation, suggesting that, like in animal research,
genetic tools are viable and vital for investigating human olfaction. We first address the basic
questions of the human olfactory system, examining whether our assumptions based on animal
olfaction are confirmed and attempting to identify mechanisms of the olfactory system that are not
well-characterized in humans or other animals. We conducted whole exome sequencing on 52
individuals in ten families with congenital anosmia, an inherited disorder where individuals lack a
sense of smell from birth. Through selection of rare, segregating, deleterious variants, we
identified 215 genes that are associated with congenital anosmia. These genes are likely to play
a role in olfaction, and can therefore serve as a resource for further investigation of the underlying
mechanisms of basic human olfaction. We next investigated the relationship between olfactory
receptors and odor perception in order to improve our understanding of how odor information is
processed at the periphery. Here, we identified two novel associations: a variant in OR51B2 that
increases intensity perception of a key component of body odor, and two-linked variants in
OR4D6 that predict specific anosmia to the musk compound Galaxolide. Uncovering the
relationship between odors and their specific receptors is the first step to understanding how the
~400 olfactory receptors work in combination to code for odor perception. These studies make
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advances towards a comprehensive understanding of how the human peripheral olfactory system
functions and codes olfactory information into odor perception.
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CHAPTER 1 – INTRODUCTION
Overview
Over the last several decades, the field of olfaction has leveraged advances in genetics
to understand the fundamental organization of the peripheral olfactory system. For example,
researchers showed that odor information is coded in a combinatorial manner (Araneda, Kini, &
Firestein, 2000; DeMaria & Ngai, 2010; Katada, Hirokawa, Oka, Suwa, & Touhara, 2005; Malnic,
Hirono, Sato, & Buck, 1999; Zhao et al., 1998), olfactory receptors are expressed monoallelically
in olfactory sensory neurons (OSNs) (Mombaerts, 2004), and all OSNs expressing the same
allele project to a common glomerulus in the olfactory bulb (Mombaerts, 2006; Mombaerts et al.,
1996). They also identified the molecular components of the OSN signal transduction pathway
(Belluscio, Gold, Nemes, & Axel, 1998; Brunet, Gold, & Ngai, 1996; Dhallan, Yau, Schrader, &
Reed, 1990; Lin, Arellano, Slotnick, & Restrepo, 2004; Wong et al., 2000). This research has
primarily investigated the olfactory system of model organisms and, although many of these
findings are assumed to apply to the human olfactory system, in many cases that evidence is
weak or nonexistent. In some cases these differences are already clear: humans have fewer
functional olfactory receptors than the commonly studied rodent species (Glusman, Yanai, Rubin,
& Lancet, 2001; Matsui, Go, & Niimura, 2010; Olender et al., 2012), but approximately twice as
many glomeruli, which implies major differences in organization within the peripheral olfactory
system (Lane, Zhou, Noto, & Zelano, 2020; Maresh, Rodriguez Gil, Whitman, & Greer, 2008).
Much of the success in understanding the olfactory system in rodents and flies has been
through the use of genetic methods ranging from the initial cloning of the olfactory receptor genes
(Buck, L. B., Axel, 1991), to knockout models of individual receptors or systematic elements of
the olfactory system (Belluscio et al., 1998; Brunet et al., 1996; Dewan, Pacifico, Zhan, Rinberg,
& Bozza, 2013; Sato-Akuhara et al., 2016; Wong et al., 2000), to more recently developed
systems allowing for unique expression of a chosen olfactory receptor (D’Hulst et al., 2016;
1

Dobritsa, Van Der Goes Van Naters, Warr, Steinbrecht, & Carlson, 2003; Hallem, Ho, & Carlson,
2004).
The general idea of using genetic tools is to relate specific genes, or differences in genes
to a function, behavior, or perception. Use of genetic tools in humans poses an extra challenge
compared to animals, as we cannot perform genetic manipulation. In mice, for example, we can
examine a single gene function at a time by knocking out the gene and comparing behavior in
mice with and without the gene. By contrast, examination of human genetics relies on natural
genetic variation, where many genes are varying at once, requiring larger samples to identify
meaningful associations between genetics and behavior by averaging out noise from genetic
variation in non-associated genes. Luckily, advances in genetic sequencing technologies and
computation have made genetic sequencing faster and less expensive, making this approach
feasible in humans. Though genes are more difficult to isolate in human genetic studies, humans
are unique amongst species in their ability to easily report perceptual differences in olfaction.
While in non-human species behavioral tests and manipulations to study smaller behavioral or
perceptual changes is challenging and time consuming, humans can quickly report complex
perceptual attributes through rating scales and surveys, such as how “fruity” or “grassy” an odor
may smell.
Here, we aim to take advantage of the power of genetic tools to identify genes in humans
with two main goals: 1. To test if our assumptions based animal olfaction hold in humans and/or
to understand elements of the olfactory system that may differ in humans by searching for genes
that may be causal for congenital anosmia, and 2. To understand the relationship between
olfactory receptors and perception of odor and how perception is coded by receptor activation, by
looking for genetic variants that predict specific cases of known differences in odor perception or
specific anosmia (inability to smell a single odor).

2

Genetic Tools in Animals Led to Major Breakthroughs in Understanding the
Basics of the Olfactory System and Olfactory Coding
The human olfactory system allows us to detect and identify a vast number of unique
odors in our environment. Odors enter our noses and are absorbed by the olfactory mucosa at
the olfactory epithelium, where they interact with receptors on the cilia of the olfactory sensory
neurons (OSNs) present there. Activated receptors produce a signal in the OSNs which carry the
signal to glomeruli in the olfactory bulb, and from there the signal is carried to higher processing
areas, such as the piriform cortex, also known as the primary olfactory sensory cortex.

Signal transduction in the olfactory sensory neurons
The first step in converting external odor stimuli to an internal representation occurs when
odor ligands bind to receptors. Humans have approximately 400 functional olfactory receptors
(Glusman et al., 2001; Olender et al., 2012), alongside other odor receptors, such as (TAARs)
and MS4As (Borowsky et al., 2001; Greer et al., 2016; Liberles, 2009; Liberles & Buck, 2006).
The family of mammalian OR genes was first identified through homology and cloning from RNA
harvested from rat olfactory epithelium tissue (Buck, L. B., Axel, 1991). These ORs were found to
be G Protein-coupled receptors (GPCRs) on the OSN membrane. Activation of ORs initiates the
transduction cascade that leads to action potentials in the OSN. Transduction of the olfactory
signal employs an adenylyl cyclase messenger activated by the G-protein Gɑ-olf that in turn
activates a cyclic nucleotide-gated channel, allowing for ion influx and propagation of the signal.
The main components of this pathway, Gɑ-olf (Belluscio et al., 1998), AC (Wong et al., 2000), and CNG
(Brunet et al., 1996), were confirmed through mouse knockout (KO) models that displayed
anosmic phenotypes through behavior and/or lack of electrophysiological response to odors. This
suggests that genetic mutations in homologous genes in humans (GNAL, ACIII, and CNGA2,
respectively) could cause of congenital anosmia (Feldmesser et al., 2007). To date, among the
transduction cascade genes, only CNGA2 mutations have been identified in individuals with
3

inherited congenital anosmia (Feldmesser et al., 2007; Karstensen, Mang, Fark, Hummel, &
Tommerup, 2014; Sailani et al., 2017), suggesting that most cases are not due to mutations
affecting the transduction cascade.

Olfactory receptors
ORs transduce chemical binding into neural information, and understanding that
transformation gives us insight into how the brain organizes odors. For every sensory system,
there are a limited number of receptors that can detect the vast amounts of information in our
environment. There are three receptors that code for color vision, meaning the entire visual
spectrum of light is compressed into only three input channels, but can result in the perception of
millions of distinguishable colors (Linhares, Pinto, & Nascimento, 2008) through further neural
processing. We know the response function of the three color receptors to wavelength of light,
which means that we understand the link between the outside world and our internal
representation. Comparatively, we understand very little in human olfaction, where only 11% of
ORs have an identified ligand (Peterlin, Firestein, & Rogers, 2014). Identifying ligands for ORs, a
process known as deorphanization, is a critical step in order to understand how odor stimuli
translate to olfactory perception.
Early attempts to deorphanize receptors in rodents and drosophila examined odorresponse profiles directly in animal models with over-expression of specific ORs (Hallem et al.,
2004; Zhao et al., 1998). In vitro expression of ORs in heterologous cells has also resulted in
advances in identifying ligands (Krautwurst, Yau, & Reed, 1998; Matsunami, Mainland, & Dey,
2009), a method that has also been applied with some success for human ORs (Mainland et al.,
2013; Mainland, Li, Zhou, Liu, & Matsunami, 2015; Saito, Chi, Zhuang, Matsunami, & Mainland,
2009). While this method is high-throughput, it has several disadvantages (Peterlin et al., 2014;
Trimmer & Mainland, 2017), for example: it has been less successful in identifying ligands for
humans ORs than mice ORs (Saito et al., 2009). Further, in vitro responses may not replicate in
4

vivo function (Trimmer et al., 2019; Trimmer, Snyder, & Mainland, 2014), which may be due to
proposed technical difficulties resulting from missing cellular components and odor binding
proteins that would normally exist in vivo, and/or issues with surface expression of the receptors
(Zhuang & Matsunami, 2008).
Given the difficulties using these gene-expression methods with human ORs, it is not
surprising that the knowledge of human ORs is far behind rodents and drosophila. A huge effort
was made in drosophila to map the full representation of odor stimuli from receptors to glomeruli
(Münch & Galizia, 2016). In contrast to the 11% of the ~400 human ORs with identified ligands
(Peterlin et al., 2014), all but one OR in Drosophila have been deorphanized. While many of
these human receptors have only a single known ligand, the Drosophila database includes
receptor response profiles to more than 100 different odorants (Münch & Galizia, 2016). This
means each Drosophila receptor has multiple identified ligands with known magnitude of
activation response. This breadth of receptor information is closer to the state of human color
vision, where we can map out the receptor responses given a wavelength of light. Currently, in
human olfaction, we are unable to even predict what receptors an odor may activate due to how
little we know of specific ligand-receptor interactions. Finally, while no human ORs have been
mapped to a specific glomerulus, all but one Drosophila glomerulus have been matched to the
projecting OSNs (Münch & Galizia, 2016).
With the formation of this Drosophila odor-response mapping database, we continue to
observe the utility of genetic tools in understanding the olfactory system. Here, this effort was
aided by the Drosophila empty-neuron system (Dobritsa et al., 2003; Hallem et al., 2004), which
allows for the expression of a selected OR in vivo. The nearly complete mapping of the
Drosophila peripheral olfactory system provides the foundation for understanding more complex
aspects of odor processing, such as how receptor interaction in the olfactory system is coded into
a percept.

5

Organization of the peripheral olfactory system: from OSNs to olfactory bulb
In peripheral odor processing, the olfactory system is organized by receptor, such that
each OSN expresses one type of receptor and glomeruli in the olfactory bulb receive projections
from OSNs expressing a common receptor.
It is generally accepted that odorant receptors are expressed monoallelically, such that
each OSN expresses a single allele of an OR or TAAR, although, unlike in rodents, this has yet to
be thoroughly examined by single-cell RNA-seq in humans (Dalton & Lomvardas, 2015;
Mombaerts, 2004). OSNs project to glomeruli in the olfactory bulb, and these projections are
organized by receptor-type, such that each glomerulus receives projections from OSNs
containing the same OR or TAAR (Johnson et al., 2012; Mombaerts, 1996; Mombaerts et al.,
1996). The first evidence of this organization pattern was observed using a genetic tool in mice
where a reporter was expressed alongside a mutated receptor, allowing for imaging of projections
from OSNs to glomeruli (Mombaerts, 1996; Mombaerts et al., 1996). It is less clear how
glomerular organization is representative of odorant receptor response in humans, but there is
evidence that this may function differently from rodents (Maresh et al., 2008). Nevertheless, the
regulation of receptor-based organizational features in the early processing of olfactory
information suggests that understanding the receptors is an essential step towards understanding
olfactory coding.

Olfactory information is coded by the combination of activated receptors
Genetic tools have allowed us to understand the basic organization of the peripheral
olfactory system, in which one OR is expressed in each OSN and each OSN projects to one OB
glomerulus. What information does each of these single-stream channels carry and how do the
channels interact in order to code for complex odor stimuli from the environment?
In a simple one-to-one coding system, each odorant activates a single receptor and each
receptor is activated by a single odorant. In such a system, we could solve olfactory coding by
6

knowing a single ligand for each receptor, and we could detect exactly as many odorant stimuli as
we have ORs. Since the number of detectible odorous molecules are larger than the number of
ORs (Mayhew et al., 2021), multiple receptors must play a role in uniquely coding for a given
odorant.
Breakthroughs in olfactory coding were made through the use of genetic tools that
allowed for the in vivo observation that a single odorant activated more than one receptor, and
that a single receptor was activated by more than one odorant (Malnic et al., 1999). This and
follow-up research came to understand this as the olfactory combinatorial code, meaning that
odorant information is coded by the unique pattern of receptors that are activated (Araneda et al.,
2000; Buck & James, 2004; DeMaria & Ngai, 2010; Malnic et al., 1999). Therefore, information
from a single chemical molecule is compressed into multiple input channels that are then
processed by the olfactory bulb.
Although we understand coding to be combinatorial, relating the unique pattern of
activated ORs to an olfactory percept still presents many challenges to the field. By analogy, if
you want to know how to bake a cake, it is not enough to know that you have to mix ingredients
together. You need a recipe to know what ingredients to use and how much of them. More
recently developed genetic tools, such as optogenetics (Wilson, Serrano, Koulakov, & Rinberg,
2017), are currently being used to understand how altering the response of a single receptor
changes the olfactory percept.

An individual OR can change the perception of an odor
We understand that odorant information is coded by the combination of receptors that it
activates; however, it is not clear how the individual receptors are contributing to the percept of
the odor. If you lose a single OR, does the activating odor/s smell more or less intense, does it
have different odor character (i.e. less “fruity”, more “green), or how often does the loss of the
receptor have no effect on the odorant? It is also possible that losing a receptor could have a
7

large impact on perception of one activating odor, but little or no discernible difference on another
activating odor. By analogy, your cake may be pretty similar if you leave out the ¼ tsp. of nutmeg,
but if you’re missing the flour, it’s another story.
There are several cases, from genetic knockout (KO) models in mice, demonstrating that
one receptor alone can significantly affect the percept of an odor (Dewan et al., 2013; Q. Li et al.,
2013; Sato-Akuhara et al., 2016). Mice missing the muscone-activating receptor, Olfr1440
(mouse OR) (Shirasu et al., 2014), were unable to find muscone in a search task, except at very
high concentrations of the odor (Sato-Akuhara et al., 2016). Two examples of the importance of a
single receptor come from the TAAR family, which are specific detectors of amine compounds.
Different amine compounds are found in urine of conspecifics and predators, and wild-type (WT)
mice show natural attraction or aversion, respectively, to these specific amines. Aversion to
amines found in predator urine and attraction to trimethylamine (TMA) found in mouse urine, were
extinguished in mice missing TAAR4 (Dewan et al., 2013) and TAAR5 (Q. Li et al., 2013),
respectively, suggesting each behavioral response is mediated by a single receptor.
KO models are advantageous for examining behavioral changes based on a specific
gene because the process of creating the KO animal results in background genetic homogeneity
between the KO and wild-type (WT) mice, in essence isolating the KO gene as the source of
genetic variability. From the examples above, it is clear that KO models are effective when the
phenotypic outcomes are large changes in behavior or perception, such as losing the ability to
detect an odor. While KOs are useful for examining these gross aspects of olfactory coding,
where a receptor has a large effect on detection of an odor, behavioral assays in mice are not as
well suited to assess smaller changes in perception that may be caused by losing a receptor,
such as a switch in odor percept from “fruity” to “grassy”. Rating an odor for perceptual changes
in odor intensity, pleasantness, or character/quality is a relatively easy task in humans, so a
human equivalent of a KO would be ideal for uncovering the granular aspects of olfactory coding.
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Peripheral olfactory organizational principles that determine olfactory coding may be different in
humans
Genetic tools in rodents and insects have lead us to understand the basic organizational
logic of the peripheral olfactory system, where each OSN has one receptor, and each glomerulus
receives information from one OSN, and the olfactory bulb acts as a readout of the combinatorial
code of external odorant stimuli. This organization pattern where each glomerulus is an
independent channel representing the response of a single receptor type forms the basis of most
coding models in the field. While the olfactory system is thought to be evolutionarily conserved
amongst mammalian species, there is evidence that humans may differ from the commonly
studied rodent species in the organization of glomerular inputs (Lane et al., 2020).
In rodents, projections from each OSN-type (OSN containing the same receptor)
converges on one medial and one lateral glomerulus in the olfactory bulb (Mombaerts et al.,
1996; Ressler, Sullivan, & Buck, 1994; Vassar et al., 1994). This is supported by the fact that that
rodents have approximately twice as many glomeruli as ORs (Maresh et al., 2008; Meisami,
1990). Humans, on the other hand, have ~400 functional ORs (Olender et al., 2012), but ~5,600
glomeruli (Maresh et al., 2008), suggesting that each OR could converge on as many as 16
glomeruli, 8 times the expected amount given the current knowledge of glomerular organization
based on rodent research.
If, in humans, glomeruli do not represent a single channel of receptor information, many
existing coding models would fail to describe human olfactory coding. This suggests that either
olfactory coding in humans is different than in other species, or that existing models based on
rodents are flawed. For example, we assume that missing one OR (i.e. the OR is non-functional)
results in a missing information channel from OSN to the OB, but if the OSN expresses a second
OR, than the information channel remains. The canonical olfactory system organizational
principles form a foundation for how we think about olfactory coding in humans, and confirming
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the similarities or finding differences in these elements in humans is a vital piece to our basic
conception of olfactory coding.
While genetic tools have already helped us understand the olfactory system in other
animals, it is clear that we remain ignorant of the extent and impact of differences that may exist
in humans. Using genetic and phenotypic variation in humans, we can uncover genes involved in
olfactory processes that may be unique to or different in humans. We can also examine subtleties
of odor perception that can only easily be reported by humans, and this can lead to
understanding of the role of individual receptors in the combinatorial code.

Genetic Tools can Improve our Understanding of Human Olfaction
Much of what we know in olfaction is due to genetic research in animals. Similar genetic
methods can also be used directly in humans for the purpose of understand basic elements of the
system and coding of stimuli. Genetic tools are particularly powerful in studying sensory systems
where there is behavioral variation alongside genetic variation, Color vision research successfully
applied genetics in humans to make foundational discoveries, and serves as a trailblazing
example for how we can gain insight into the human olfactory system. By using genetic tools in
humans we can directly study systematic and receptor-based elements of olfaction that can help
us understand the process of olfactory coding.

Color vision is a trailblazing example for how human genetics can uncover the basics of a system
While primary olfactory stimuli are encoded by ~400 receptors, color vision employs only
three receptors (photopsins) to encode the visible light spectrum. Before the genes for
photoreceptors were identified, there were known phenotypic variations in color vision, and
several different types of color blindness had been classified by psychophysics research. In 1986,
Nathans and colleges set out to identify the genes encoding photoreceptors, with the goals of
understanding color blindness and, more generally, uncovering the biomechanics of spectral
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sensitivity as determined by amino acid sequence of the photopsins (Nathans, Thomas, &
Hogness, 1986). They discovered that the green and the red opsins were 98% identical in
sequence and adjacent to each other on the X-chromosome, suggesting that the high probability
of recombination between these two already similar genes causes opsin variants that are less
sensitive to difference in that part of the spectrum, leading to red-green color deficiency (Nathans
et al., 1986; Piantanida, 1988). This led to the discovery of genetic variation in opsins even
amongst those with normal color vision, which eventually resulted in an exact quantification of the
shifts in spectral sensitivity caused by each variation in amino acid sequence (Neitz & Neitz,
2011; Piantanida, 1988).
From the culmination of genetic research in color vision, we can now predict the
phenotypic photospectrum of every individual based solely on the genetics of their three
photoreceptors (Neitz & Neitz, 2011; Piantanida, 1988). The ability to predict phenotype from
genotype is one of the ultimate goals in understanding olfaction; and although we are far from this
goal, olfaction and color vision have a common set of tools that suggests genetic research could
be as powerful in understanding olfaction as it was in uncovering the molecular underpinnings of
color vision.

The human “knockout” model
Generally, the genetic tools in animals allow us to create individual variation in genetics
and then observe the resulting behavioral changes. The genetic tool most analogous to our
research in humans is the knockout model. As discussed earlier, knockout models were used to
identify contributions of specific receptors in odor coding, and demonstrate the necessity of
olfactory-specific proteins involved in the transduction pathway (Belluscio et al., 1998; Brunet et
al., 1996; Dhallan et al., 1990; Lin et al., 2004; Wong et al., 2000). Although we are unable to
actively manipulate the human genome to make genetic knockouts in humans, we can sequence
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the genome to identify sites of natural genetic variation, and examine if those variations correlate
with differences in odor perception.
The success of this methodology for olfaction relies on the same two essential elements
that exist in color vision: genetic variation and phenotypic variation. The potential drawback of this
genotype/phenotype correlation approach in humans is that we cannot study genes without
variants or odors without perceptual differences. Fortunately, as I will discuss below, there is a
plethora of known differences in odor perception alongside an unusually large amount of genetic
variation within a protein family, suggesting there are ample opportunities to conduct this type of
research in the olfactory system.

The toolbox: genotypic and phenotypic variation
For vision, people vary from the norm with different types of specific color deficits, the
most common of which is red-green color deficiency. In olfaction, there are many studied
examples, and even more canonical examples, of differences in odor perception (HasinBrumshtein, Lancet, & Olender, 2009) ranging from complete loss of the sense of smell
(anosmia) (Karstensen & Tommerup, 2012; Landis, Konnerth, & Hummel, 2004) or inability to
smell certain odors (specific anosmias) (J. E. Amoore, 1967; John E. Amoore, 1977; John E.
Amoore & Forrester, 1976; Baydar, Petrzilka, & Schott, 1992; Bremner, Mainland, Khan, & Sobel,
2003; Whissell-Buechy & Amoore, 1973), to more minor perceived differences in the character,
pleasantness, or intensity of an odor (Gilbert & Kemp, 1996; Keller, Hempstead, Gomez, Gilbert,
& Vosshall, 2012; Keller & Vosshall, 2016; Charles J. Wysocki & Gilbert, 1989).
Of course, in order for phenotypic differences to be explained by genetics, there has to
be sufficient genetic variation in the system. The olfactory receptors in the olfactory system
display an unusually high level of genetic diversity (Menashe, Man, Lancet, & Gilad, 2003;
Olender et al., 2012), with an estimated 2.5 times higher rate of variants per base pair than any
average coding exon (Olender et al., 2012). Further, this genetic variability may be responsible
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for significant phenotypic differences between people, as about 1/3 of OR alleles are predicted to
be functionally different between any two people (Mainland et al., 2013). We currently have little
understanding of how most of these genetic differences affect perception of odor. Using
genotype/phenotype association methods in humans can not only help us understand how
specific receptors are contributing to coding olfactory information, but can also lead to better
understanding of the mechanism at the level of the odor-receptor interaction, with the goal of
someday having the ability to predict what odors will bind to a receptor based only on the
structure of the protein, as is now the case with color vision.
Looking beyond ORs, it is harder to determine the degree of genetic variation within the
more broad set of genes that are necessary for the olfactory system, partly because the main
source of information for which genes are necessary comes from rodent models. However, efforts
have been made to compile information from humans and rodents to prioritize a list of genes
associated with general olfactory capability, known as the General Olfactory Sensitivity Database
(GOSdb) (Keydar et al., 2013). Of the top 136 genes in the GOSdb priority list, there are 1,818
deleterious variations (Keydar et al., 2013), suggesting that there is plentiful functional genetic
variation to utilize in human genetic methods for understanding the function of general olfactory
genes.

Genetic tools have been used successfully in olfaction to discover the role of individual human
genes
We are now able to use our knowledge of the collection of genetic tools in other model
systems to directly study elements of olfaction in humans. One example of translating genetic
tools and knowledge built from non-human systems to humans was the process of understanding
the role of the odorant receptor, trace amine-associated receptor 5 (TAAR5). TAARs are a class
of receptors specific for detecting amines, and were discovered using the same genetic methods
that lead to the discovery of the OR gene family (Borowsky et al., 2001; Liberles & Buck, 2006).
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Genetic tools further lead to the discovery that TAARs were expressed in the olfactory epithelium
of rodents and humans (Carnicelli, Santoro, Sellari-Franceschini, Berrettini, & Zucchi, 2010;
Liberles, 2009) and projected to a specific subset of OB glomeruli in rodents (Johnson et al.,
2012), demonstrating that TAARs were odorant receptors that functioned similarly to, but
distinctly from ORs (Pacifico, Dewan, Cawley, Guo, & Bozza, 2012).
To gain insight into the TAARs, researchers employed a heterologous cell system and
identified specific amine ligands for rodent TAARs (Ferrero et al., 2012). These experiments
showed that the strongest agonist for mouse and rat TAAR5 was trimethylamine (TMA), a fishy
smelling odor, and this was later confirmed by cell assay for the human homolog, hTAAR5
(Wallrabenstein et al., 2013). To understand the contribution of TAAR5 to perception of TMA, Li
and colleagues (2013) demonstrated that TAAR5 was necessary for the natural behavioral
attraction to TMA, which is found in mouse urine (Q. Li et al., 2013). Since this attraction to TMA
is a mouse-specific behavior, as rats avoid TMA and humans find it aversive (Q. Li et al., 2013), it
was still unclear how TAAR5 might contribute to human perception of TMA. Specific anosmia to
TMA had long since been documented in humans (John E. Amoore & Forrester, 1976) without a
known genetic cause.
Building on all of the evidence gathered through genetic tools, Gisladottir and colleagues
(2020) conducted genotype/phenotype association in a large, and specific, population to find a
rare variant in TAAR5 that influences aversion to TMA in humans (Gisladottir et al., 2020). The
combination of tools building from cells through rodents led to the discovery of a role of a specific
receptor directly in humans, demonstrating both the power of genetic tools and how to apply
these methods in humans.

The challenges of using genetic tools in humans
The olfactory system is an ideal landscape for employing genetic studies in humans, as it
contains an unusually large degree of genetic and phenotypic variation in order to study genes
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influencing olfactory perception from general olfactory capabilities to specifics of odor perception.
While genetic variation is necessary to be able to conduct genotype/phenotype association
studies, is also poses a challenge. The rodent knockout models are bred to have a genetically
homogeneous background, but humans will have many genetic variants across the genome, with
the vast majority unrelated to the phenotype of interest. The example from color vision shows
that it is possible to overcome these challenges, as genetic variation in the photopsins existed in
people with and without deficits in color vision, but nonetheless, researchers identified causal
genes.
To overcome the challenge of a noisy genetic landscape, we have employed different
strategies in the study design of each project. In the first project, where we searched for genes
that may cause congenital anosmia, we recruited families with recurring cases of congenital
anosmia. This allowed us to take advantage of the family structure to select for genetic variants
based on inheritance pattern within each family, thus reducing the effect of a heterogeneous
genetic background.
In the second project, we identified genetic variants that associated with differences in
odor perception in order to improve understanding of olfactory coding at the level of receptor. In
order to overcome the genetically heterogeneous background we took advantage of advances in
sequencing technology that have made it more efficient to collect large amounts of data.
Examining large populations is necessary to achieve enough statistical power to average
outcomes across unrelated genetic variants (statistical noise), and achieve significant signal in
potentially causal variants. Through a collaboration, we had access to a population of 1000
individuals (B. Li et al., 2022). This population was not only large, but was relatively
homogeneous from a human population demographics perspective, as all individuals were of Han
Chinese descent. We further increased our power of discovery by recruiting a separate
population of 364 individuals to validate the initial findings.
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The field has reached a point where it is necessary to close the information gap between
rodent and human olfaction in order to understand the basic elements of the olfactory system and
olfactory coding, and the only way is by directly studying humans. Genetics has been used as a
powerful tool for discovery in sensory systems in humans, and olfaction has both phenotypic and
genotypic variation that can be harnessed in order to employ these tools. Here, we will probe
genetics of both the general olfactory system by examining families and individuals with
congenital anosmia, and receptor-based olfactory coding by identifying ORs related to odors with
known perceptual variation. These projects contribute to our understanding of human olfaction
systematically, and in coding and perception.

Harnessing Genotypic and Phenotypic Variation to Understand Human Olfaction
Here, my aim is to study the genetics underlying two phenotypic phenomena, specific
anosmia and congenital anosmia, in order to improve our understanding of human olfaction.
Anosmia, or the inability to smell, can exist in isolated cases, where individuals are unable to
smell a particular odor (specific anosmia), or as a global congenital disorder, where an individual
inherits the inability to smell anything from birth (congenital anosmia). Examining congenital
anosmia may elucidate previously unknown genes that play a role in human olfaction or confirm
knowledge of the olfactory system that originated in other animal models, while looking at specific
anosmias may uncover the roles of individual receptors in the OR combinatorial code.

Isolated Congenital Anosmia
Prior to the COVID-19 pandemic, an estimated 5% of the population was reported to
experience anosmia (Karstensen & Tommerup, 2012), with many of these cases arising from
known injury or disease, such as viral infections, head trauma, or neurodegenerative disorders.
By contrast, congenital anosmia is a relatively rare disorder affecting approximately 1 in 10,000
people (Feldmesser et al., 2007). There are a few known syndromes that can cause congenital
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anosmia, and have known genetic underpinnings (Karstensen & Tommerup, 2012); however,
isolated congenital anosmia (ICA), or nonsyndromic anosmia, remains largely enigmatic, as only
two genes have been identified to date (A. Alkelai et al., 2016; Anna Alkelai et al., 2017;
Feldmesser et al., 2007; Ghadami et al., 2004; Karstensen et al., 2014; Moya-Plana, Villanueva,
Laccourreye, Bonfils, & De Roux, 2013; Sailani et al., 2017; Temmel et al., 2002). Although
general olfactory ability has been shown to vary by genetic (Keydar et al., 2013; Pinto,
Thanaviratananich, Hayes, Naclerio, & Ober, 2008) factors (as well as non-genetic factors, such
as age and sex (Doty & Cameron, 2009; Keller et al., 2012; Raj et al., 2021; Charles J. Wysocki &
Gilbert, 1989)), little is known about the necessity of these genes to olfaction in humans. As the
goals of this project is to test if olfactory-related genes identified in other animal models are
necessary in humans and uncover new genes that may be necessary for olfaction, we are
examining the anosmia phenotype in individuals with isolated congenital anosmia, as their lack of
olfactory function is inherited, so must have an underlying etiology in genes necessary for
olfaction.
Genetic studies on ICA have made it clear that this is a genetically heterogeneous
disorder, meaning that there are a plethora of different mutations in different genes that arise in
separate families with ICA (Anna Alkelai et al., 2017; Feldmesser et al., 2007; Karstensen &
Tommerup, 2012; Keydar et al., 2013). This suggests that there are many yet undiscovered
genes in the etiology of ICA, which presents an opportunity to uncover a variety of different
genes, some of which may not have previously been known to play a role in the olfactory system,
thus improving our knowledge of olfaction directly in humans.
There are many genes that are known to play a role in olfaction (Keydar et al., 2013), and
specific study of these has not been sufficient to fully explain etiology of ICA (Feldmesser et al.,
2007). Early targets for examining congenital anosmia were genes in the olfactory transduction
pathway as these genes were determined to be necessary to olfaction from research in KO
mouse models, and some of them may be specific to olfaction (Belluscio et al., 1998; Brunet et
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al., 1996; Dhallan et al., 1990; Lin et al., 2004; Wong et al., 2000). Feldmesser and colleagues
(2007) examined three of these genes (CNGA2, GNAL, ADCY3) in 64 unrelated humans with
anosmia and found no variants that were not also present in their control sample (Feldmesser et
al., 2007). Later, however, two groups found different mutations in CNGA2, the gene coding the
cyclic nucleotide-gated channel present in the olfactory transduction pathway (Karstensen et al.,
2014; Sailani et al., 2017). It is clear that although the olfactory transduction pathway may be
affected in some families with ICA, these genes do not account for all of ICA etiology. Our
research expands the search to account for the genetic heterogeneity of ICA.
Other genes that could cause ICA may be related to development of the olfactory system.
In one of the syndromic forms of anosmia, Kallman’s syndrome, many of the identified causal
gene variants are related to formation of the olfactory bulb or connectivity to it (Karstensen &
Tommerup, 2012). Mutations in two of these genes identified in Kallman’s syndrome, which are
directly involved in olfactory bulb development (PROKR2 and PROK2), have also been identified
in individuals with ICA who do not experience other symptoms of Kallman’s syndrome (MoyaPlana et al., 2013), mainly delayed or absent puberty. Kallman’s syndrome is caused by the
underdevelopment of olfactory neurons and gonadotropin-releasing hormone (GnRH) neurons,
which develop in the nose and later migrate to the hypothalamus. Other genes identified in
Kallman’s syndrome, or other syndromic disorders with anosmic symptomology may also appear
in ICA, providing insight into the olfactory-specific mechanisms of these genes.
The only other gene that has been identified in cases of ICA, TENM1, plays a role in
development of neural connectivity (A. Alkelai et al., 2016). This gene was shown to be involved
in neuronal development in several species, plays a role in synapse organization in the
drosophila, and causes an anosmia-like phenotype in a mouse knockout model (A. Alkelai et al.,
2016).
The current research into ICA has implicated genes involved in the olfactory transduction
pathway and development of neurons both in structure and connectivity, but there are many other
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olfactory-related pathways where disruption could cause ICA. Other genes affecting olfactory
development in structure or connectivity of the olfactory bulb, olfactory epithelium, or even nasal
passage are likely candidates. This constitutes a wide variety of candidates, as even genes that
code for cell adhesion or cytoskeletal proteins could play a role in development. Another class of
genes that may be relevant to ICA are those that impact the ability of odorous molecules to
interact at the receptors. These would include genes involved transport of molecules to the
receptors, such as those that code for odorant binding proteins or other proteins that make up the
olfactory mucosa where odorant are absorbed (Karstensen & Tommerup, 2012). Our research
seeks to find genes related to ICA so that we can better understand the basics of human
olfaction.
In Chapter 2, I discuss our research in the genetics of ICA. We have sequenced families
and individuals with ICA and produced a candidate list of genes that are likely to contribute to ICA
etiology. The field has been limited in its understanding of ICA having had few previous candidate
genes to work from. Linking specific genes to ICA suggests they play a necessary role in
olfaction, such that their dysfunction causes anosmia. While there are many genes with some
known relationship to olfaction72, many of these have resulted from studies in non-human
species. The heterogeneity of ICA and the lack of sufficient etiology for the disorder provides us
with an opportunity to fill the gap in knowledge about human olfaction, whether by confirming
known olfactory-related genes directly in humans, or by finding genes that may play previously
unknown roles in the olfactory system.

Specific anosmias
Humans have a plethora of variability in the way their perceive odors, and in the genetics
of the receptors that are responsible for detection of these odors (ORs). We know from studies in
animal models that external olfactory information is coded by the combination of receptors
activated by the odor, yet, little is known about the specific human ORs in terms of what odors
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they recognize and how the combination of activated ORs codes for odor perception. Here, we
are using the phenotypic and genotypic variation to elucidate the role of individual ORs with the
goal of better understanding the olfactory combinatorial code at the level of the receptor.
It has been well established that there is variability in people’s perception of smell: early
published examples date back more than 100 years (Blakeslee, 1918; Hasin-Brumshtein et al.,
2009). Perception of specific odors also varies by individual, classified by three main categories:
1) anosmia – the inability to smell an odor, 2) hyposmia – decreased sensitivity to an odor, 3)
hyperosmia – increased sensitivity to an odor. A large body of literature confirms abundant
variation in single odorant perception resulting in changes in many phenotypes, such as odor
detection threshold, pleasantness or intensity rating, and odor character (John E. Amoore, 1977;
John E. Amoore & Forrester, 1976; Blakeslee, 1918; Bremner et al., 2003; Gilbert & Kemp, 1996;
Hasin-Brumshtein et al., 2009; Keller & Vosshall, 2004, 2016; Keller, Zhuang, Chi, Vosshall, &
Matsunami, 2007; Menashe et al., 2003; Whissell-Buechy & Amoore, 1973; Charles J. Wysocki &
Gilbert, 1989).
Although phenotypic variation in odor perception is influenced by factors such as cultural
background, age and sex (Doty & Cameron, 2009; Keller et al., 2012; Raj et al., 2021; Charles J.
Wysocki & Gilbert, 1989), it has long been clear that there are genetic underpinnings beyond
these factors. Before genotyping was prevalent, Wysocki and Beauchamp (1984) demonstrated
the genetic underpinnings of androstenone, an odorous compound with high rates of specific
anosmia (Bremner et al., 2003; Charles J. Wysocki & Gilbert, 1989), by examining anosmia rates
in twins (C J Wysocki & Beauchamp, 1984). Interest in the genetic underpinning of androstenone
anosmia led to the identification of a receptor, OR7D4 (Keller et al., 2007; Knaapila et al., 2012a;
B. Li et al., 2022; Trimmer et al., 2017), which is responsible for detection of androstenone and
explains between 3-39% of phenotypic variation in androstenone intensity perception (Keller et
al., 2007; B. Li et al., 2022). This demonstrates that OR genetics factor into perceptual
differences in odor, and genotype-phenotype studies can be used to identify specific roles of
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receptors in perception. It is important to note that this one receptor may explain only a small
amount of perceptual variation in an odor, suggesting that even for the well-studied odor
androstenone, there is more work to be done in uncovering other receptors that work in
combination to code its perception.
In the search for genetic explanations of phenotypic diversity, association studies require
sufficient genetic variability. Olfactory receptors (ORs) comprise one of the largest mammalian
gene superfamilies (Glusman et al., 2001; Menashe et al., 2003; Olender et al., 2012). While
there are estimated to be ~400 functioning ORs in humans, the whole gene family comprises
around 851 genes, where approximately 50% are pseudogenes, or genes annotated as
nonfunctional (Olender et al., 2012). Compared to mice where ~20% of ORs are pseudogenes
(Zhang & Firestein, 2002), this is an exceptionally large number of non-functional genes.
Additionally pseudogenes are not ubiquitous in humans, and there is considerable variation in the
composition of functional ORs between humans: Menashe and colleagues (2003) found 178
different functional genomes across 189 individuals, exhibiting a high level of genomic diversity
(Menashe et al., 2003). The differences in number of pseudogenes between individuals means
that some of the annotated pseudogenes are actually segregating pseudogenes, or genes that
may be non-functional in some individuals, but are functional in other individuals, as caused by
nonfunctional mutations (i.e. frame-disrupting (insertions or deletions), stop codon gain or loss,
start codon loss) or copy number variation (CNV) mutations. It is estimated that 308 of the 851
OR genes are segregating pseudogenes (Olender et al., 2012). Receptor pseudogenization may
cause a shift in perception of odors that activate it, as a piece of the odor code is missing. Due to
our lack of understanding of the receptor combinatorial code, it is unclear if losing a receptor will
result in specific anosmia, or smaller changes in intensity, pleasantness or character of the odor.
Pseudogenization mutations have a clear functional result, but do not account for all of
the differences in odor perception. Another potentially major genetic cause of phenotypic changes
are missense mutations, or substitutions of a single nucleotide (single nucleotide polymorphisms;
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SNPs) that result in changes in the amino acid code in the resulting protein. Missense mutations
are also prevalent, occurring 2.2 times as often in the human ORs than in a set of control genes
(Olender et al., 2012). The outcome of a missense mutation on receptor function is variable
based on where it occurs in a protein, and may result in increase or decreased activation to
odors, activation to different odors, or could have no discernible functional effect.
The field has begun to make advances in understanding the role of specific ORs in the
combinatorial code by utilizing the high level of genotypic and phenotypic diversity present in the
olfactory system. To date, there have been more than 30 cases identified where genetic variation
in an OR has been linked to phenotypic variation in odor perception (Eriksson et al., 2012; Gilbert
& Kemp, 1996; Gisladottir et al., 2020; Hasin-Brumshtein et al., 2009; Jaeger et al., 2013; Jaeger,
Mcrae, Salzman, Williams, & Newcomb, 2010; Knaapila et al., 2012a; B. Li et al., 2022; Mainland
et al., 2013; McRae et al., 2013, 2012; Menashe et al., 2007, 2003; Trimmer et al., 2019; C J
Wysocki & Beauchamp, 1984). Advances in genetic sequencing technology now allows for
collection of large genetic databases which can be probed for phenotypic differences in odor. For
example, the association between the “soapy” flavor of cilantro and a mutation near the region of
the genome containing OR6A2 was identified through a survey of over 26,000 participants in the
23andMe genomic database (Eriksson et al., 2012).
In Chapter 3, we will discuss our work in collaboration with a group at the Chinese
Academy of Sciences to collect phenotypes for 10 odors in a population of 1000 individuals of
Han Chinese descent who had been previously sequenced for health research. We conducted
GWAS in this population to determine associations between odor phenotypes and genetic
variants, and validated these associations in a smaller population of 364 individuals (B. Li et al.,
2022). The results of this work contribute to better understanding of the role of individual
receptors which is essential for the eventually understanding of how odor information is coded in
humans.
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Conclusion
Genetic tools have contributed throughout the history of olfactory research, creating a
framework for how external olfactory stimuli are processed in the peripheral olfactory system.
Much of the body of this research has been conducted in Drosophila and rodents, with little direct
confirmation in the human system. In fact, direct human research does not support the one-toone receptor-to-OSN-to-glomerulus framework which informs the field’s notion of olfactory coding,
confirming the need for study of these peripheral olfactory elements directly in humans. The work
discussed in the following chapters utilizes the power of genetic tools by harnessing the inherent
genetic and phenotypic variation present in human olfaction, with two main goals: 1) Test our
understanding of the olfactory system that is based on animal models directly in humans, and
discover elements that differ in human olfaction, and 2) Learn how individual ORs contribute to
odor perception with the ultimate goal of understanding how ORs work in combination to translate
external odor information into perception.
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CHAPTER 2 – IDENTIFYING CANDIDATE GENES UNDERLYING ISOLATED
CONGENITAL ANOSMIA
Contributions: Marissa L. Kamarck, Casey M. Trimmer, Nicolle R. Murphy, Kristen M.
Gregory, Darren W. Logan, Luis R. Saraiva, and Joel D. Mainland

Abstract
An estimated 1 in 10,000 people are born without the ability to smell. Despite the
importance of olfaction for our quality of life, the genetic basis for these cases of congenital
anosmia remains largely unknown. We conducted whole exome sequencing (WES) in ten
families with a history of congenital anosmia in the absence of other syndromes (isolated
congenital anosmia; ICA). Through selection steps, we identified a candidate list of 220 rare,
segregating, deleterious variants in 215 genes. This list includes previously implicated ICA gene
CNGA2, which is an essential component of the olfactory transduction pathway. Historically,
identification of genes related to other sensory disorders has provided a gateway to better
understanding of those senses. This study provides a more comprehensive picture of the
spectrum of genetic alterations and their etiology in ICA patients, which may improve the
diagnosis, prognosis, and treatment of this disorder and lead to a better understanding of the
mechanisms underlying basic olfactory function.

Introduction
Prior to the COVID-19 pandemic, it was estimated that 5% of the population experienced
anosmia, or total loss of smell (Landis et al., 2004). A smaller segment of the anosmic population
(~3%) (Karstensen & Tommerup, 2012; Temmel et al., 2002) experience anosmia from birth,
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termed congenital anosmia (CA), which can be isolated (or non-syndromic; ICA) or exist as a
symptom of a syndrome (Karstensen & Tommerup, 2012)(i.e. Kallman’s syndrome).
Despite the importance of olfaction for quality of life, the genetic basis for ICA remains
largely unknown. To date, only eight genes (A. Alkelai et al., 2016; Anna Alkelai et al., 2017;
Karstensen et al., 2014; Keydar et al., 2013; Moya-Plana et al., 2013; Sailani et al., 2017) have
been identified for ICA. This inadequacy of genomic information in ICA stands in stark contrast
with the genetic etiology of other non-syndromic inherited sensory deficits, where there are
almost 100 genes implicated in congenital deafness (“Hereditary Hearing Loss,” n.d.; Stelma &
Bhutta, 2014) and over 200 genes implicated in congenital blindness (Sahel, Marazova, & Audo,
2015). Similar to inherited deficits in other sensory systems, ICA is a heterogeneous disorder (A.
Alkelai et al., 2016; Anna Alkelai et al., 2017; Feldmesser et al., 2007; Ghadami et al., 2004;
Karstensen et al., 2014; Karstensen & Tommerup, 2012; Sailani et al., 2017), likely having a
multitude of causal genes with different potential patterns of inheritance that remain to be
uncovered.
Genes involved in hereditary hearing loss are involved in different functional pathways
such as morphology of structural elements of the auditory system (such as cytoskeletal and
adhesion proteins), auditory signaling (such as signal transduction, ion homeostasis, and
synapse development and regulation), protein transport (localization of cellular elements for
proper functioning), or general development of anatomy and connectivity in the system (Stelma &
Bhutta, 2014). Likewise, we would expect genes associated with congenital anosmia to cause
olfactory dysfunction through varied underlying mechanisms.
Six of the eight causal genes that have been identified for ICA have also been implicated
in Kallman’s syndrome (PROK2, PROKR2, FGFR1, SEMA3A, CHD7, ANOS1) (Anna Alkelai et
al., 2017; Moya-Plana et al., 2013), which presents with anosmia alongside deficiencies in
gonadotropic-releasing hormone (GnRH) resulting in hypogonadotropic hypogonadism. The
common underlying mechanism for these two symptoms results from disruptions in neurons
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during early embryonic development as the GnRH neurons of the hypothalamus arise from the
area that later becomes the olfactory epithelium (Schwarting, Wierman, & Tobet, 2007; ValdesSocin et al., 2014). This highlights the role of developmental genes in olfactory dysfunction,
potentially through disruptions in neuronal migration, axon guidance, synaptogenesis, or other
developmental functions in regions from which olfactory structures arise.
Other genes that could cause ICA could be involved in olfactory signaling or signal
transduction. CNGA2 has been found in two families with ICA (Karstensen et al., 2014; Sailani et
al., 2017), and is an essential piece of the olfactory transduction pathway, as mice lacking
CNGA2 lose the ability to smell (Brunet et al., 1996). Other elements of the rodent olfactory
transduction pathway have not yet been confirmed in human genetic studies (Belluscio et al.,
1998; Feldmesser et al., 2007; Wong et al., 2000). SCN9A had also been shown to cause
anosmia, although this gene has not been identified specifically in patients with ICA. SCN9A
codes for a voltage-gated sodium channel that is expressed in the olfactory epithelium and is
responsible for propagation of the signal to the terminal synapse, such that mice missing SCN9A
have an anosmic phenotype and fail to evoke synaptic transmission of signal past the primary
olfactory sensory neuron (Weiss et al., 2011; Zufall, Pyrski, Weiss, & Leinders-Zufall, 2012). The
role of SCN9A has been confirmed in humans as mutations in this gene have been identified in
several individuals with insensitivity to pain coupled with anosmia (Bogdanova-Mihaylova,
Alexander, Murphy, & Murphy, 2015; Zufall et al., 2012). The complex and multi-genetic nature of
ICA suggests that these or other signaling-related factors could function as underlying
mechanisms for ICA.
Causal genes for ICA could also lead to anosmia via unanticipated mechanisms. Several
of the previously identified ICA genes have known involvement in olfaction with knockout
phenotypes causing anosmia, or affecting formation of the olfactory bulb or olfactory epithelium
(Keydar et al., 2013). However, TENM1 (A. Alkelai et al., 2016), was identified in ICA without an
identified role in olfaction prior to publication (A. Alkelai et al., 2016), suggesting the opportunity to
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uncover genes that may more generally contribute to our knowledge of olfactory function in
humans.
Since much of our knowledge of the canonical olfactory system functioning is derived
from other species and remains to be confirmed in humans (Lane et al., 2020), evidence in
humans for genes that are correlated with anosmia can provide insight into essential components
of human olfaction. In this study, we conducted whole exome sequencing on 10 families with
inherited patterns of ICA in order to search for candidate genes for ICA that were enriched for
rare, deleterious mutations. This study aims to provide a comprehensive picture of the spectrum
of genetic variation in ICA. Discovery of the genes underlying ICA can aide in understanding of
the etiology of this disorder, which may improve the diagnosis, prognosis, and treatment of this
disorder and lead to a better understanding of the mechanisms underlying basic olfactory
function.

Results
Participants and anosmia phenotype
In order to generate a list of candidate genes underlying the etiology of congenital
anosmia, we conducted whole exome sequencing on 52 (23 male) participants worldwide from
within ten unrelated families, each with at least two participating anosmic individuals (25 anosmic
participants, 11 male) and one self-reported normosmic individual (27 self-reported normosmic
participants, 12 males). All families had at least two participating normosmic individuals except
Family 24. Self-reported olfactory dysfunction status was confirmed for 49 out of the 52
participants using the Brief Smell Identification Test (BSIT). Two reported normosmic participants
had BSIT scores consistent with abnormal olfactory capabilities, although not necessarily
indicative of anosmia. One of these participants was not integral to the inheritance model, so was
removed from further analysis (participant 250 from Family 25). The status of the other participant
(40 from Family 13) indicated the inheritance pattern for Family 13, so both inheritance models
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were applied. One participant self-reported hyposmia, but their BSIT score was within the
normosmic range and they were considered normosmic in the analysis. Participants were
between 19-87 years of age (mean = 45) and had no other reported genetic syndromes known to
cause olfactory dysfunction. This study was conducted remotely, therefore we relied on selfreport for medical conditions.

Selected variants
We selected for variants that most likely underpin the etiology of congenital anosmia in
10 families (Figure 1). By studying families, we can select for segregating variants that are
inherited only by family members with anosmia, and rule out variants with genotypes that also
persist in normosmic participants. As it is a rare disorder (approximately 1 in 10,000 people have
congenital anosmia (Karstensen & Tommerup, 2012; Landis et al., 2004; Temmel et al., 2002)),
the most likely candidates for disease-casing status of congenital anosmia are variants that are
rare in the general population and that are also predicted to significantly disrupt the gene such
that it no longer codes for a functional protein.
Following these three filtering steps (inherited variants, rare variants, deleterious variants
(Figure 1, Table 1), we selected 220 unique variants from the original 557,459 variants that
resulted from our quality-controlled preprocessing pipeline. These 220 variants comprise our
“Candidate List” (Table 2) and are annotated in 215 different genes that may underly the etiology
of congenital anosmia.

Selecting inherited variants within families
Variants were first selected by inheritance pattern within each family. The potential
inheritance of causal genes for congenital anosmia was determined by examining the collected
pedigrees for each family (Figure 2). Based on these pedigrees, six families were analyzed using
a model for dominant inheritance, and three were analyzed using a model for recessive
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inheritance. One Family (Family 13) was analyzed with dominant and recessive models, due to
the ambiguous anosmia diagnosis for a participant whose pedigree position indicates the
inheritance pattern (participant 40; Figure 2-marked with a star). Additionally, seven families were
evaluated using an X-linked inheritance model, of which five families produced X-linked variants
that were not selected by the dominant or recessive models. There were 33,910 unique
segregating variants selected from the original set of 557,459 (Figure 2, Table 1). 2,549 of the
variants occurred in more than one unrelated family.

Selecting rare variants
Congenital anosmia occurs in less than 0.5% of the population, so we expect any causal
variants to be at least as rare. We selected 2,290 of 31,986 dominant and 118 of 2,336 recessive
variants using minor allele frequency (MAF) cutoffs of 0.005 of 0.07 respectively (Figure 3),
meaning that if the variant caused anosmia, fewer than 0.5% of the population would be anosmic.
7 of 77 X-linked variants passed the 0.07 cutoff. In total, we selected 2,404 unique rare,
segregating variants, 7.1% of those selected by models of inheritance, and 0.4% of the original
set (Table 1).

Selecting deleterious variants and creating priority variant lists
The most likely candidates for disease-casing status are variants that significantly disrupt
the gene such that it no longer codes for a functional protein. We selected highly deleterious
coding variants using the recommended CADD score cutoff (Rentzsch, Schubach, Shendure, &
Kircher, 2021) (CADD PHRED-ranked score >10) and then removed non-coding variants. 434
deleterious variants were selected out of the 2,404 rare, segregating variants (Figure 4). The
majority of the non-coding variants were filtered by CADD>10, as only 21 additional variants (of
1,516 “modifier” variants) were removed due to VEP annotation.
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The 434 variants were categorized into low (n=109, 10<CADD<15), medium (n=105,
15<CADD<20), and high (n=220; CADD>20) priority lists based on predicted deleteriousness by
CADD score (Table 1). The following results will focus on 220 variants from the high priority list
(Candidate List), selected by CADD scores >20 (Table 2).

High priority gene list
We selected 220 segregating, rare, and highly disruptive variants as high priority for
examination in the potential etiology of congenital anosmia (Figure 5). These 220 variants were
located in 215 different genes. One variant was identified in two different families (rs34338164),
and 4 genes had variants in more than one family (NEBL, MYO3A, TLN2, PLEK) (Table 2). We
conducted a search of these 215 genes using the VarElect tool (Stelzer et al., 2016) to annotate
these 215 genes with a score (VarElect Score) for how related the gene is to an input phenotype,
and whether the relationship is direct or indirect (by interaction with other directly related genes).
67 of our genes had a previous direct relationship to olfactory or anomia phenotypes, 146 had an
indirect relationship, and 2 had no previous association with olfaction or anosmia. These two
genes are nonetheless still candidates for follow-up studies, as they may be involved in anosmia
or olfaction in previously unestablished ways.

Three high priority genes
We chose three genes that are exemplary of the filtering pipeline leading to the highest
priority list of 215 candidate gene for congenital anosmia.

CNGA2
The identification of a variant in CNGA2 validates the effectiveness of our variant
selection pipeline, as loss of function mutations in CNGA2 have been identified in two other
families with congenital anosmia (Karstensen et al., 2014; Sailani et al., 2017), and deletion of the
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mouse ortholog results in anosmia (Brunet et al., 1996) (Table 3). CNGA2 codes for the cyclic
nucleotide-gated channel which functions in the olfactory transduction pathway. Here, we
identified a rare stop gain mutation in CNGA2 (rs1396710739) with a dominant inheritance
pattern in Family 25 (Figure 6a). Our high priority gene list did not include any other genes from
the olfactory transduction pathway (GNAL, ADCYIII) or genes previously identified in congenital
anosmia (TENM1, ANOS1, PROKR2, PROK2, SEMA3A, CHD7, FGFR1) (A. Alkelai et al., 2016;
Anna Alkelai et al., 2017; Moya-Plana et al., 2013).

FCRL6
FCRL6 (Figure 6b) is marked as an expression partner for CNGA2, as well as the
Kallman’s syndrome associated gene FGF17 (Table 4). Ontologically, it is predicted to play a
supportive role to MHC proteins (Major histocompatibility complex), as well as enabling
transmembrane receptor signaling. The FCRL6 stop gain mutation in Family 4 (rs61823162) had
the highest predicted deleteriousness of any variant selected by a recessive model of inheritance
(Figure 5).

MYO3A
MYO3A codes for the actin-motor protein MyosinIIIA, which plays a known role in
sensory perception in the vision and audition modalities (Walsh et al., 2011) (Table 3). We
identified two rare missense mutations in MYO3A with the dominant inheritance model
(rs1286612883 in Family 24 and rs72787346 in Family 7; Figure 6c). Identification of multiple
rare, deleterious mutations in MYO3A flagged this gene as a target for further study.

Congenital anosmia candidate gene ontology
To determine the general function of the 215 candidate genes and how they may be
related to olfaction and anosmia, we used gene ontology information provided by VarElect
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(Stelzer et al., 2016) and GeneCards (Safran et al., 2021) (www.genecards.org). Most of the
genes discussed below were labeled directly related (Table 3) to olfaction/anosmia, and those not
discussed below had evidence for expression in the olfactory system (olfactory bulb, olfactory
mucosa, or olfactory sensory neurons), or human ontology phenotypes related to sensory
perception. Genes labeled as indirectly related (Table 4) to olfaction/anosmia are matched to
implicating genes (directly related to olfaction/anosmia) that have shared pathways, expression,
or gene families.

Genes involved in development of the olfactory system
Many of the candidate genes annotated by VarElect scores as related to olfaction may
affect olfactory function through abnormal development of structures or connectivity. One
candidate gene (DCC) is causal for Kallman’s syndrome (Bouilly et al., 2018), which is
characterized by hypogonadotropic hypogonadism and anosmia. The link between these
symptoms arises from the co-localization of anterior GnRH-expressing hypothalamic and
olfactory neurons in embryonic development (Schwarting et al., 2007; Valdes-Socin et al., 2014).
Six genes (CPLANE1, KIAA0586, CEP63, EVC2, PDE6A, DNAAF11) were implicated in
ciliopathy syndromes, such as Joubert’s syndrome and Bardet-Biedl syndrome, which can
present with anosmia. Ciliopathies can often result in facial deformities, cranial developmental,
and/or sensory perception issues. Therefore, genes common to ciliopathies could cause olfactory
dysfunction by impacting the development of nasal structure, neuronal connectivity, or even direct
obstruction of olfactory signaling through the malformation of cilia responsible for detecting odors
on the olfactory sensory neurons (Challis et al., 2015).
Two genes (PHYH and RETREG1) were associated with other disorders (Refsum
disease and hereditary neuropathy, respectively) that had anosmia phenotypes, however the
relationship between the gene function and the olfactory system is unclear.
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Three genes (POLG, ERCC6, TRPM7) were strongly implicated in phenotypes with
abnormal peripheral nervous system development, potentially affecting morphology of the cranial
nerve. At least 5 other genes had weak evidence for this phenotype, but were either less well
characterized, or were characterized for hearing or vision disorders. Two genes (PTPRS and
GRID2IP) coded for proteins with function involving synaptic development, and one gene (NAV2)
was implicated in development of sensory organs, with suggested olfactory dysfunction
phenotypes.

Olfactory signaling
The candidate gene list identified one known gene from the olfactory transduction
pathway, CNGA2, which codes for the cyclic nucleotide-gated channel expressed in olfactory
sensory neurons (Figure 6a).
A group of candidate genes were generally implicated in functions or phenotypes that
could affect olfactory signaling by maintaining or promoting ion levels and ion exchange. PCDH9
plays a role in calcium ion binding and signaling, and has a known variant associated olfactory
ability (Dong et al., 2015). SYT17 is expressed in the olfactory bulb and codes for a protein that
enables calcium ion binding activity. There are two identified solute carrier genes that could play
a role in signaling via ion maintenance. SLC22A codes for a protein that transports cations, and
SLC24A1 codes for a protein that functions as a sodium/calcium exchanger and has known roles
in maintaining signaling in vision. A third solute carrier gene, SLC30A, codes for a zinc
transporter protein. Zinc has been shown to enhance olfactory signaling to odorants through a
direct interaction at the olfactory receptor (Vodyanoy, 2010).
Another route for affecting olfactory signaling is by direct interaction with the odorants.
The candidate gene BPIFB2 codes for a BPI fold containing protein, which is in a family of
proteins suggested to function as odorant-binding proteins, transporting odorants to receptors
(Andrault, Gaillard, Giorgi, & Rouquier, 2003). Two cytochrome P450 family members (CYP27A1
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and CYP4Z1) were on the candidate list. These could potentially be involved in biotransformation
or clearance of odorants, as other cytochrome P450s have been shown to play such a role in
olfaction (Lazard et al., 1990).

Discussion
Isolated congenital anosmia (ICA) is a genetically complex disorder, but only a handful of
causal genes have been identified. Here we have identified 220 rare, segregating and deleterious
variants in 215 genes that are putatively causal for congenital anosmia.
Previous studies on the genetics of congenital anosmia have focused on genes involved
the olfactory transduction pathway (Feldmesser et al., 2007; Karstensen et al., 2014; Sailani et
al., 2017) or genes that are causal for Kallman’s Syndrome (Anna Alkelai et al., 2017; MoyaPlana et al., 2013), a genetic disorder characterized by hypogonadotropic hypogonadism
alongside anosmia, concluding that congenital anosmia is a heterogeneous disorder likely caused
by many different genes. In the 10 families studied here, only 4 out of the 215 genes had rare,
segregating, deleterious variants in more than one family, suggesting that most families have
unique genetic underpinnings for anosmia. CNGA2 is the most commonly occurring genetic
factor, having been previously identified in two families with congenital anosmia (Karstensen et
al., 2014; Sailani et al., 2017). Here, we identified a rare stop gain mutation in CNGA2, supporting
the role of this gene in olfaction. This serves as a positive control for our study, demonstrating
that our selection process can identify causal genes for congenital anosmia.
Other than CNGA2 (Karstensen et al., 2014; Sailani et al., 2017) and TENM1 (A. Alkelai
et al., 2016), all previously identified genes for ICA were also implicated in Kallman’s syndrome or
other syndromes with hypogonadotropic hypogonadism (6 genes: PROK2, PROKR2, SEMA3A,
FGFR1, CHD7, ANOS1) (Anna Alkelai et al., 2017; Moya-Plana et al., 2013). It had been
suggested that Kallman’s syndrome genes may also be playing a large role in ICA (Anna Alkelai
et al., 2017). None of the six syndromic genes previously associated with ICA were selected for
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the high priority list; however, we identified one syndromic gene, DCC (Bouilly et al., 2018), that is
novel to ICA. This suggests that in our families, unlike in previous research, Kallman’s syndrome
genes are not a major cause of ICA.
The genes causing Kallman’s syndrome frequently lead to olfactory deficits because of
the proximity of the hypothalamus and olfactory tissues during embryonic development
(Schwarting et al., 2007). We identified more than 10 genes that code for proteins with pivotal
roles in development including formation of olfactory anatomical structures, neuronal
development, axonal projection, or neuronal migration. The exact role of these identified genes in
olfaction could be examined in future studies by first confirming expression in olfactory epithelium
and/or olfactory bulb through a search of RNAseq databases and validation in mice. Expressed
genes can be further examined in knockout or knockdown models in mice or other animal
models, such as zebrafish, for olfactory behavioral phenotypes and olfactory system morphology.
Anosmia could also be caused by disruption of normal olfactory signaling at the level of
the OSNs or olfactory bulb. CNGA2 codes for the cyclic nucleotide-gated (CNG) channel that is
an essential element in the initial transduction of olfactory signal, as evidenced by mouse CNGA2
knockouts who demonstrated the anosmia phenotype (Brunet et al., 1996). In the OSN,
transduction of the olfactory signal occurs when an odorant binds to the olfactory receptor,
initiating a cyclic AMP second messenger pathway that opens CNG channels that allow influx of
sodium and calcium ions. Intracellular calcium then opens channels allowing for efflux of chloride,
the cumulation of which results in cell depolarization. The candidate list includes 4 genes which
enable calcium ion binding or transport. Improper modulation of the calcium ion concentration or
binding could result in disruptions of the olfactory signal. Future studies could establish a role for
these genes involved in olfactory signaling by modeling specific variants in human cellular models
by CRISPR/Cas9 gene editing followed by assays that allow for measurement of cell activation,
such as calcium-flux assays.
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The genetic data provided in this study can be used as a resource for future studies
interested in congenital anosmia or the human olfactory system in general. One strategy for
further prioritizing these genes is to start with genes that play a role in olfaction, as described
above. Another strategy could prioritize the most highly deleterious mutations, starting with loss of
function mutations (i.e. stop gain, frameshift, splicing). There are 36 genes from the candidate
gene list annotated as loss of function mutations. The genes could also be prioritized by family.
Larger pedigrees provide stronger evidence for the applied inheritance model and more
participants within reduces the potential for identification of irrelevant variants. In our study,
Family 1 has the most participant and largest pedigree. Genes identified for Family 24 have the
highest chance of irrelevancy, as this family was the only family with one normosmic family
member, meaning other normosmic family members are more likely to have other copies of the
selected variants.
The number of potential candidate genes could also be expanded from our high priority
list. We have provided a list of all genes that are predicted to have some deleterious qualities (in
low and medium priority lists). Further, we chose to examine only non-coding mutations, but our
data includes high-quality reads in regions upstream and downstream of annotated genes that
could be analyzed for involvement in disrupting gene expression. Finally, our segregation
analysis included only three inheritance models (dominant, recessive, and X-linked). The data
could be further mined for models that allow for incomplete penetrance or multiallelic inheritance.
Give the rarity of ICA, we designed this study to be conducted by mail. As a result, we do
not have structural MRIs for these participants and participants with non-genetic causes may be
included. We should note, however, that even a structural MRI is not sufficient to rule out nongenetic causes. Similarly, without a full medical history we may miss syndromic symptoms. On
the other hand, this design allows us to collect data from far more families.
Few genes have been identified for ICA, yet it is a heterogeneous disorder with many
potential genes that may be involved. We have identified a list of 220 variants in 215 genes that
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are promising candidates for isolated congenital anosmia. Many of the genes in our candidate list
have unknown roles in olfaction, or only presumed roles based on co-expression or common
pathways with olfactory or olfactory-disease related genes, yet many of these genes have also
not been well-characterized in humans. Much of what we assume is true in human olfaction is
derived from research in animal models (Lane et al., 2020). By nature of the disorder, genes
involved ICA must play a necessary role in olfaction, so discovery of more causal genes can
provide insight into the underlying mechanisms of basic human olfaction.
In other sensory disorders, causal gene identification has led to improvement of
diagnoses, and development of potential treatments. Identifying the genetic basis for ICA is the
first step in developing targeted therapeutics for ICA, a disorder that currently has no viable
treatments and very little information to offer to affected patients. We hope this resource will
change our limited knowledge of this disorder and provide a foundation for individuals that
currently have no other options.

Materials and Methods
Study participants
We recruited 10 completed families (52 individuals, 25 with congenital anosmia) between
19-87 years of age (mean = 45) with inherited patterns of congenital anosmia (CA). Data
collection was conducted remotely resulting in 42 participants recruited from with the United
States and 10 recruited internationally. Each family had at least two participating individuals with
congenital anosmia and at least one participating normosmic control (Figure 7). With the
exception of one family (Family 24), all families had two or more control individuals. Collection of
data was approved by the University of Pennsylvania Institutional Review Board and all
individuals provided written consent.
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Participant data collection
Participants completed a basic screening questionnaire either verbally, or electronically
using REDCap software (Harris et al., 2019, 2009). Congenitally anosmic patients were classified
by self-report, having no sense of smell from birth and no known syndromes or genetic disorders
(i.e. Kallman’s syndrome) (Karstensen & Tommerup, 2012). Participants provided a saliva
sample (Oragene DNA collection tube) and completed the 12-item University of Pennsylvania
Brief Smell Identification Test (BSIT) (Doty, Shaman, Kimmelman, & Dann, 1984) under direct
instruction of a research associate via phone or video to confirm normal or abnormal olfactory
ability. The number of correct answers was converted into a percentile rank of olfactory function
relative to age and sex using the BSIT scoring manual. All self-reported anosmic individuals were
classified as having abnormal olfactory ability. One participant self-reported hyposmia (participant
256), or reduced sense of smell, but scored in the normal range on the BSIT, so was analyzed as
normosmic in Family 47. Two self-reported normosmic individuals (participants 250, and 40) were
classified as having abnormal olfactory ability for their age by the BSIT. Participant 250 from
Family 25 was not included in the family analysis, as their anosmia status did not change the
family inheritance model. Participant 40 from Family 13 was determinant for the chosen
inheritance model, so was included in the family analysis, and both inheritance models were
used.

Whole exome sequencing
Whole exome sequencing was performed on genomic DNA extracted from saliva
samples (Oragene Discover 2mL kit and protocol). Samples were sequenced in three cohorts
comprising different facilities, capture kits, and technologies. 36 samples were sequenced at
Wellcome Sanger Institute DNA sequencing team (Cambridge, UK) using the Illumina HiSeq2500
platform and the Agilent SureSelect V5 capture kit. 6 samples were sequenced at Sidra Medicine
Integrated Genomics Services (Doha, Qatar) using the Illumina HiSeq2500 platform and the
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Agilent SureSelect V6 capture kit. 10 samples were sequenced at Children’s Hospital of
Philadelphia (CHOP) Research Institute Center for Applied Genomics Sequencing Core
(Philadelphia, PA) using the Illumina NovaSeq 6000 platform and the Twist Whole Exome
Sequencing + RefSeq capture kit. 8 samples from the Sanger and Sidra facilities were
resequenced at the CHOP facility to control for differences that might arise from sequencing with
different technologies and capture kits. With few exceptions, samples from within each family
were sequenced at the same facility.
Sequences were aligned to the GRCh38 genome build using the BWA aln algorithm
(version 0.7.12) (H. Li & Durbin, 2009) and cleaned with Picard Tools (v2.22.1) (“Picard toolkit,”
2019). The remaining preprocessing and variant calling steps followed the Broad Institute GATK
recommended ‘best practices’ using GATK4 (v4.2.4.1) (Depristo et al., 2011; McKenna et al.,
2010a; Poplin et al., 2017; Van der Auwera et al., 2013). Further filtering was performed to
remove low quality variants marked by GATK, variants with > 5% genotype missing frequency,
and variants that deviated from Hardy-Weinberg equilibrium (HWE; p < 1x10 -5), resulting in
57,459 biallelic single nucleotide polymorphism (SNP) and indel (insertion/deletion) variants.

Variant annotation
Variants were annotated with the VEP (Variant Effect Predictor; Ensembl) (Cunningham
et al., 2022; McLaren et al., 2016), and custom scripts in R (R Core Team, 2021). Annotation
information included gene names, gene location (i.e. intron, exon, UTR, etc.), variant
consequence (i.e. missense, nonsense, insertion/deletion), predicted impact of variants on
protein (PolyPhen (Adzhubei et al., 2010), SIFT (Vaser, Adusumalli, Leng, Sikic, & Ng, 2016),
CADD (Rentzsch et al., 2021)), and minor allele frequency (1000 Genomes Project (Auton et al.,
2015), ALFA (Phan et al., n.d.)).
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Variant selection for inherited, rare, disruptive mutations
The full data for number of variants per family at each step of the selection process is
reported in Table 1. Variants were first selected based by inheritance model (i.e. dominant,
recessive, X-linked) determined separately for each family based on the pedigree information
reported by probands. 6 families were modeled for dominant inheritance, 3 families were modeled
for recessive inheritance, and one family was modeled for both dominant and recessive (Family
13). 7 of the families also were analyzed by an X-linked inheritance model. The anosmic status of
Family 13, participant 40, was unclear (see BSIT section above), and their status determined the
inheritance model used (Figure 7). Family 13 was therefore analyzed by a dominant model with
participant 40 as anosmic, and by a recessive model with participant 40 as normosmic. This
selection step resulted in 33,910 unique segregating variants.
Rare variants were selected based on the minor allele frequency (MAF) as reported in
the general population. The 1000 Genomes Project database (Auton et al., 2015) provided MAF
for 26,561 of the 33,910 variants, leaving 7,439 variants with missing MAF. The NCBI ALFA
database (Phan et al., n.d.) was searched by VEP-annotated RefSeq accession number to
provide population MAF for 6,838 additional variants, leaving 513 missing MAF. After the
described filtering steps, only 5 variants missing population MAF data remained in the final gene
list. The combined MAF data was used to select rare variants by inheritance model, using
MAF<0.005 for the dominant model, and MAF<0.07 for recessive and X-linked models, resulting
in 2,404 variants. These cutoff values are more strict than previous literature examining genetics
of congenital anosmia (Anna Alkelai et al., 2017), and roughly follow the frequency with which we
would expect to find causal variants for congenital anosmia, based on the estimate that 1/10,000
people have congenital anosmia (Karstensen & Tommerup, 2012; Landis et al., 2004; Temmel et
al., 2002).
Non-coding variants and non-deleterious variants were filtered out by selecting for CADD
PHRED-ranked score >10 (Rentzsch et al., 2021), and excluding variants with VEP annotated
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impact =“MODIFIERS”, resulting in 434 variants. These remaining 434 variants were categorized
into low (n=109, 10<CADD<15), medium (n=105, 15<CADD<20), and high (n=220; CADD>20)
priority lists based on predicted deleteriousness by CADD score (Table 1). The high priority gene
list with CADD PHRED-ranked score >20 includes variants that are predicted to be in the top
99.99% deleteriousness of all variants.

Genes in olfactory transduction pathway and ICA
We searched the selected variants from low, medium, and high priority gene lists for
genes related to the olfactory transduction pathway (CNGA2, ADCYIII, GNAL) (Feldmesser et al.,
2007), the two genes previously identified only in isolated congenital anosmia (CNGA2
(Karstensen et al., 2014; Sailani et al., 2017), TENM1 (A. Alkelai et al., 2016)), and six genes
linked to Kallman’s syndrome that have also been identified in individuals or families with ICA
(PROK, PROKR2, FGFR1, SEMA3A, CHD7, ANOS1/KAL1) (Anna Alkelai et al., 2017; MoyaPlana et al., 2013).

Determining gene relationship to olfaction/anosmia using VarElect
The VarElect NGS Phenotyper tool from the GeneCardsSuite (Stelzer et al.,
2016) determines whether genes are directly (via known disorder/syndrome/association in
literature) or indirectly (i.e. gene-gene interactions, or gene-related pathways) related to a
phenotype and provides a phred-weighted score based relevance of the genes to the phenotype
within the GeneCardsSuite database. A higher score indicates that the gene is more likely to be
associated with the input phenotypes (i.e. olfaction/anosmia). We used this tool to determine
relatedness to olfactory and anosmia phenotypes (olfact* OR smell OR anosmia) for the 215
genes on our high priority list.
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220

Figure 1. Anosmia Variant Selection Pipeline.
A graphical representation of the three main selection steps (inheritance model by pedigree, rare
variants by minor allele frequency (MAF), deleterious variants by CADD PHRED-ranked score).
The numbers represented at each step are the number of variants that were selected at that step.
The final candidate list consisted of 220 variants in 215 genes (Table 2).
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Figure 2. Selected Variants within Family by Anosmia Inheritance.
33,910 variants were selected of the original 557,459. In these treemaps, the areas of the
rectangles are proportional to the number of variants in the division. The total area of the left
treemap is 560,165, as some variants were selected by multiple families and/or multiple
inheritance models. The space is divided into removed variants and three categories of selected
variants by model of inheritance pattern. The “Removed Variants” area represents 523,526
variants which did not cooccur with anosmia status based on the inheritance models. The
“Selected Variants” area represents 36,616 segregating variants, of which 33,910 are unique, and
2,549 were selected in more than one unrelated family. 492 of the 2,549 repeating variants were
chosen by more than one inheritance model. Of the selected variants, 34,176 (31,986 unique)
were selected by dominant models (yellow), 2,362 (2,339 unique) were selected by recessive
models (green), and 78 (77 unique) were selected by for X-linked models (blue). The right
treemap is a magnification of the “Selected Variants” area of the left treemap such that the whole
area is represented by the 36,616 selected variants. The number of variants selected for each
family is represented by the area of their labeled rectangle. The family areas are further
subdivided into inheritance pattern for those families for whom multiple models of inheritance
were used (yellow=dominant, green=recessive, blue=X-linked). The variants selected by X-linked
model are represented, but often not visible due to the comparatively small numbers. X-linked
models were used in Families 3, 7, 9, 25, and 47. The number of variants selected for each family
and inheritance model are in Table 1. Each family space includes an abbreviated pedigree in
order to visualize the reasoning behind the selected inheritance model. The pedigrees include
both participants(black), and non-participating family members (lighter grey), where anosmic
individuals have filled in shapes, and normosmic individuals have open shapes. Full pedigrees for
each family are included in Figure 7.

45

Figure 3. Selection of Rare Genes by Minor Allele Frequency (MAF).
Minor allele frequency (MAF) in the general population was collected for each variant based on
data from the 10000 Genomes Project (Auton et al., 2015) or from NCBI Allele Frequency
Aggregator (ALFA) (Phan et al., n.d.). Cutoff values of 0.005 for dominant (yellow line) and 0.07
for recessive and X-linked (green line) variants were employed to select 2,404 unique variants
(black) of the of the 33,910 inherited variants. 31,506 variants were filtered out (grey). 513
selected variants were missing allele frequency information, and are represented here in black at
MAF=0.
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Family 7

Family 6
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200
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600

# Variants
Figure 4. High Priority Variant List by Family.
Variants with CADD PHRED-ranked score> 20 were selected for the high priority list. These 220
unique variants are most likely to be causal for congenital anosmia in the 10 families studied
here. Each bar represents the total number of variants per family that were selected by
inheritance pattern and MAF, with the darker color representing the final selected variants by
CADD score (>20) (see Table 1 for final numbers per family). Families are colored by their main
inheritance pattern (yellow=dominant, green=recessive). The ambiguous Family 13 had one
remaining variant from the recessive filter and 13 from the dominant filter. Only Family 7 had one
variant from the X-linked filter, although other genes on the X chromosome were captured by the
dominant filter.
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Relationship to
Olfaction

CNGA2
PHYH
OR2W3

DCC
OR1B1

FLG

Direct
Indirect

Known Relationship to Olfaction
log(VarElect Score)

1

TLN2

ERCC6

0

FCRL6
CEP63
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USP6

RAB22A
ASAP3

NE B
MYO3A
-1
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Deleteriousness of the Variant
CADD PHRED-Ranked Score

Figure 5. High Priority List Deleteriousness and Relationship to Olfactory Phenotypes.
Each point represents one of the 220 unique variants in the High Priority List for Congenital
anosmia. The CADD PHRED-ranked score is a measure of the deleteriousness of the genes,
with CADD scores over 20 representing variants that are more deleterious than 99% of all
predicted variants (CADD 30>99.9%, CADD 40>99.99%). VarElect Score is a measure of the
known relationship of each gene to olfactory phenotype, either directly (red), or indirectly (blue).
Genes in labeled boxes had deleterious variants in multiple families. We labeled other top genes
of interest based on those predicted to be the most deleterious, or the most related to olfaction(for
full variant and gene details see Table 2, for full VarElect details see Table 3 and Table 4).
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Figure 6. Three Candidate Genes for Congenital Anosmia.
a) CNGA2 b) FCRL6 and c) MYO3A are three genes from the 215 high priority gene list. For each
gene, there is a map of the gene structure with the exons (light blue), introns (white), and variant
(red stripe), and a pedigree for the family from whom the variant was selected. For each
pedigree, the circles represent females, and squares represent males, with filled shapes
representing individuals with anosmia and open shapes indicating normosmic individuals. Other
family-specific notations are listed (i.e. Family 25).
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Figure 7. Full Family Pedigrees.
Pedigrees for all 10 families in the study. Pedigrees follow standard notation where filled shapes
represent anosmic individuals and empty shapes represent normosmic individuals. Special cases
are indicated in keys at the bottom of the individual family pedigrees.
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Tables

Table 1. Number of Variants per Family and Inheritance Model.
The number of variants left after each of the selection steps is noted per family and inheritance
pattern under the spanner “Variant Selection Steps”. For families analyzed with more than one
inheritance model, these numbers are divided and labeled under the respective model
(“dominant”, “recessive”, or “X-linked”). Selection for rare variants used a minor allele frequency
cutoff of 0.005 for dominant models of inheritance and 0.07 for recessive and X-linked models of
inheritance. Selection for deleterious variants used a CADD PHRED-ranked score cutoff of 10,
and eliminated non-coding variants using VEP annotation. This resulted in the priority lists of rare,
segregating, deleterious variants, which are ranked by CADD PHRED-ranked score (Low:
10<CADD<15, Medium: 15<CADD<20, High (CADD>20).
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Filtering Steps

Priority Lists

Inheritance Rare Deleterious Low Medium High
Family 1
dominant

415

76

17

3

3

11

4830

395

86

17

17

52

1998

237

55

19

8

28

22

4

1

0

0

1

11791

694

118

29

30

59

2269

164

35

9

5

21

40

2

0

0

0

0

5233

450

54

14

18

22

5

1

0

0

0

0

recessive

547

23

4

2

1

1

dominant

7640
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53

14

21

18

678

46

6

2

0

4

7

0

0

0

0

0

773

36

7

1

3

3

364

16

2

1

0

1

4

0

0

0

0

0

Family 6
dominant
Family 7
dominant
X
Family 24
dominant
Family 25
dominant
X
Family 47
dominant
X
Family 13

Family 3
recessive
X
Family 4
recessive
Family 9
recessive
X
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Table 2. High Priority Candidate Gene/Variant List.
The high priority candidate list of segregating, rare, deleterious variants. The first column is the
information about the variant(chr=chromosome, bp= base position, REF=reference allele,
ALT=alternate allele). RefSeq is the unique identifier for the variant. The Gene annotation was
determined by VEP annotations. Inheritance is the model under which the variants were selected
for each Family. MAF= minor allele frequency in the general population.
Chr:bp_REF/ALT

RefSeq

Gene

Family Inheritance MAF

chr1:23441416_G/A
chr1:23796177_G/A
chr1:25246525_A/G
chr1:29053128_G/A
chr1:35609326_G/A
chr1:47106246_C/T
chr1:53216053_C/T
chr1:53835611_A/G
chr1:94007731_G/A
chr1:109342050_C/A
chr1:150578851_G/A
chr1:152308777_G/A
chr1:156657004_G/T
chr1:156736709_C/T
chr1:156938433_C/T

rs1206148186
NA
rs34619962
rs556816482
rs141977664
rs144526298
rs113278028
rs202217135
rs28938473
rs2228605
rs11580946
rs200002200
rs41267397
rs139211741
rs142548089

6
6
6
7
1
1
24
1
1
24
13
24
13
24
6

dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant

7.12e-5
NA
2.60e-03
4.00e-04
1.00e-03
2.34e-04
1.80e-03
4.00e-04
2.40e-03
3.60e-03
3.20e-03
4.00e-04
4.00e-04
2.00e-04
6.00e-04

chr1:158547753_A/T
chr1:159815623_C/T
chr1:183969313_G/A

rs138738485
rs61823162
rs144317776

24
4
6

dominant
recessive
dominant

1.20e-03 23.5
5.77e-02 35
2.00e-04 23.6

chr1:215619155_G/A
chr1:219210598_G/A
chr1:235380150_G/A
chr1:247896133_G/A
chr1:248180358_G/A
chr10:13288464_C/T
chr10:17796275_C/T
chr10:20808617_G/A
chr10:20889923_C/G
chr10:26021578_A/G

rs1464715010
rs143934381
rs200356271
rs201811838
rs199810194
rs751660253
rs1032686581
rs143584663
rs41277374
rs1286612883

ASAP3
GALE
RSRP1
EPB41
PSMB2
CYP4Z1
CZIB
NDC1
ABCA4
SORT1
MCL1
FLG
BCAN
METTL25B
ARHGEF1
1
OR6Y1
FCRL6
COLGALT
2
KCTD3
LYPLAL1
TBCE
OR2W3
OR2M2
PHYH
TMEM236
NEBL
NEBL
MYO3A

24
24
6
7
47
6
13
7
13
24

dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant

0.00e+00
2.00e-04
1.66e-04
4.00e-04
2.00e-04
0.00e+00
1.51e-03
1.40e-03
1.40e-03
7.12e-05
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CADD
Score
36
23.1
26.2
24.3
24.9
20.2
26.3
28.9
25.2
26.8
23.7
30
32
22.7
26.2

21.8
25.6
34
21.6
22.2
23.2
26.2
27
22.6
25.1

Chr:bp_REF/ALT

RefSeq

Gene

Family Inheritance MAF

chr10:26088402_C/T
chr10:27211053_C/A
chr10:34382912_T/G
chr10:49472376_C/T
chr10:114162848_A/G
chr10:118015066_G/A

rs72787346
rs370914625
rs1015152616
rs145720191
rs145366675
rs141500760

7
7
25
7
24
24

dominant
dominant
dominant
dominant
dominant
dominant

1.00e-03
4.34e-05
4.50e-05
1.40e-03
4.00e-04
3.00e-03

chr10:133167414_C/T
chr10:133459720_G/A
chr11:9178284_A/G
chr11:10853315_T/A
chr11:17599671_C/T
chr11:19892526_G/A
chr11:22755870_C/T
chr11:47754604_T/C
chr11:55265599_G/A
chr11:64365455_G/A
chr11:64368219_C/T
chr11:65116915_C/T
chr11:67507592_C/T
chr11:71482013_G/A
chr11:74457316_C/T
chr11:74907276_G/T
chr11:75443206_G/A
chr11:121452363_G/C
chr11:124016464_C/G
chr12:6560712_C/T
chr12:6563421_C/T
chr12:14425084_T/C
chr12:31102434_G/A
chr12:45050570_G/A
chr12:47717514_T/C
chr12:57786200_G/A
chr12:80549726_CTGA
AACAGGTAACTAACG/
C
chr12:98544517_G/C
chr12:122380373_G/A
chr13:25315357_G/A
chr13:32178328_G/T

rs145440398
rs775375030
rs199552458
rs190420451
rs117005078
rs142341675
rs145978353
rs34962598
rs145499448
rs145356210
rs151034403
rs375067810
rs144468375
rs147585323
rs17215437
rs143601450
rs199987196
rs147575757
NA
rs367978783
rs200105333
rs762769025
rs139972807
rs1192927184
rs763731302
rs371076990
rs141686707

MYO3A
ACBD5
PARD3
ERCC6
CCDC186
RAB11FIP
2
KNDC1
SCART1
DENND5A
ZBED5
OTOG
NAV2
GAS2
FNBP4
TRIM48
RPS6KA4
RPS6KA4
ZNHIT2
CDK2AP2
NADSYN1
KCNE3
XRRA1
GDPD5
SORL1
OR10G4
NOP2
NOP2
ATF7IP
DDX11
DBX2
ENDOU
TSFM
PTPRQ

CADD
Score
26.4
24.7
20.6
35
26.4
20.2

25
25
24
7
24
24
25
24
13
6
6
24
24
24
24
7
7
7
25
6
6
6
7
47
6
47
4

dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
recessive

1.60e-03
1.42e-04
4.88e-05
8.00e-04
1.00e-03
7.16e-04
2.00e-04
3.60e-03
4.00e-04
2.81e-04
2.54e-04
0.00e+00
3.40e-03
1.80e-03
1.00e-03
2.00e-03
5.68e-04
3.25e-04
NA
2.70e-04
4.00e-04
0.00e+00
2.00e-04
5.65e-05
4.34e-05
1.74e-04
5.04e-02

25.2
24.4
26.1
22.7
33
24
23.7
23.3
24.2
23.4
25.2
24.2
23
23.4
22.8
23.1
23.1
25.2
22.9
27.2
23.5
23
20.4
26.6
22.4
27.9
32

rs7133258
rs34292795
rs35924025
rs1593701671

TMPO
CLIP1
NUP58
FRY

1
7
47
7

dominant
dominant
dominant
dominant

2.40e-03
4.20e-03
1.80e-03
0.00e+00

22.5
22.4
32
22.6
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Chr:bp_REF/ALT

RefSeq

Gene

Family Inheritance MAF

chr13:36438683_C/T
chr13:45968957_C/T
chr13:67226966_C/T
chr13:113425093_CT/C
chr14:58432438_AG/A
chr14:92688066_C/G
chr15:24676906_G/T
chr15:43279265_G/A
chr15:44554580_C/A
chr15:50614254_G/T
chr15:58563549_C/T
chr15:62792780_C/T
chr15:62838892_C/T
chr15:64674848_C/G
chr15:65650913_T/C
chr15:84031334_G/C

rs376677628
rs143879310
rs764767362
rs530445616
rs534542684
rs376695836
rs34629208
rs148818002
rs764140621
rs1223489527
rs113298164
rs140861754
rs140301741
rs370988343
rs146253044
rs761235041

25
13
6
47
13
24
13
3
24
6
47
47
24
47
47
24

dominant
dominant
dominant
dominant
dominant
dominant
dominant
recessive
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant

2.64e-04
2.20e-03
0.00e+00
4.34e-05
2.40e-03
3.27e-04
2.00e-03
1.26e-02
0.00e+00
7.12e-05
1.20e-03
8.00e-04
6.00e-04
1.00e-03
3.00e-03
4.10e-05

chr15:89330133_C/G
chr16:1770908_C/A
chr16:9103041_G/A
chr16:19183886_C/A
chr16:19487221_C/T
chr16:23424923_C/T
chr16:64972031_G/A
chr16:84880571_A/G
chr17:1480574_C/T
chr17:5004946_G/A
chr17:5170526_A/T
chr17:6109676_C/T
chr17:6434058_C/G
chr17:8487498_C/T
chr17:10392944_G/C
chr17:18261161_G/A
chr17:21703294_T/C
chr17:28631505_G/A
chr17:50081316_A/G
chr17:50548440_A/G
chr17:68427179_G/A
chr17:75242427_T/C
chr17:78050542_G/A

rs61752784
rs1030732407
rs137974792
rs149512546
rs141281985
rs367796897
rs141063325
rs139975503
rs117696188
rs142056835
rs200143577
rs138096430
rs755639765
rs77768450
rs141215006
rs117304413
NA
rs557714329
rs141893882
rs145670888
rs755132647
rs52809447
rs71385927

CCNA1
ZC3H13
PCDH9
ADPRHL1
KIAA0586
RIN3
NPAP1
TGM7
EIF3J
TRPM7
LIPC
TLN2
TLN2
ZNF609
SLC24A1
ADAMTSL
3
POLG
NME3
C16orf72
SYT17
TMC5
COG7
CDH11
CRISPLD2
MYO1C
KIF1C
USP6
WSCD1
AIPL1
MYH10
MYH8
MIEF2
KCNJ18
KIAA0100
ITGA3
SPATA20
WIPI1
GGA3
TNRC6C
58

CADD
Score
22
21.1
23.3
23.5
33
24.6
21.1
21.6
23.2
26.1
24.1
21.3
27
23.2
27.4
33

24
24
7
6
6
47
24
47
24
25
25
25
24
25
13
24
24
24
13
13
7
6
24

dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant

2.80e-03
0.00e+00
6.00e-04
8.33e-04
0.00e+00
1.60e-03
2.60e-03
3.20e-03
8.00e-04
6.00e-04
1.00e-03
1.95e-04
5.65e-05
2.00e-04
4.60e-03
3.00e-03
NA
2.00e-04
2.00e-03
3.60e-03
6.24e-05
1.40e-03
4.80e-03

25.3
29.7
31
33
25.4
22.6
20.8
20.7
22.7
22.3
43
25.1
23.3
23.5
25.9
20.4
26.3
26.6
20.1
25.5
23.5
32
22

Chr:bp_REF/ALT

RefSeq

Gene

Family Inheritance MAF

chr18:334837_G/A
chr18:7049172_C/T
chr18:45639867_T/C
chr18:46477710_C/T
chr18:53157503_G/A
chr18:70197682_T/G
chr19:1510658_G/A

rs145828426
rs140718292
rs147437273
rs74316327
rs141813053
rs12956068
rs774891231

24
7
7
4
24
13
47

dominant
dominant
dominant
recessive
dominant
dominant
dominant

2.80e-03
2.20e-03
4.00e-04
2.72e-02
8.00e-04
1.20e-03
1.62e-04

chr19:5221216_C/T
chr19:8088093_C/T
chr19:38609919_T/A
chr19:48117686_C/A
chr19:49395147_G/A
chr2:9492963_C/T
chr2:27577302_C/T
chr2:33584784_T/C
chr2:68388414_A/C
chr2:68388414_A/C
chr2:127986906_T/C
chr2:168695047_G/C
chr2:169636565_G/A
chr2:178537015_C/T
chr2:200897104_G/A
chr2:201710994_T/C
chr2:218814154_C/T
chr2:219386963_T/G
chr2:227370939_T/A
chr2:233147519_G/A
chr20:30399220_A/G
chr20:33019745_G/C
chr20:41405261_C/T
chr20:42677904_G/A
chr20:46241014_G/A
chr20:49949294_G/A
chr20:58310013_G/C
chr20:59773332_C/T
chr21:36251267_C/T
chr22:24178086_G/A
chr22:29801042_T/C
chr22:49961012_C/A

rs771119355
rs372550025
rs1437711338
rs145821638
rs191973091
rs61754177
rs200280226
rs116221550
rs34338164
rs34338164
rs72841716
rs746130855
rs370131717
rs55742743
rs189436612
rs61757691
rs41272687
rs11539909
rs144716300
rs752600484
rs773264582
rs61734341
rs369533037
rs751487270
rs139897629
rs41303809
NA
rs148776043
rs76166909
rs144524781
rs34833047
rs772757757

COLEC12
LAMA1
SLC14A2
LOXHD1
DCC
RTTN
ADAMTSL
5
PTPRS
FBN3
MAP4K1
LIG1
KASH5
ADAM17
C2orf16
FAM98A
PLEK
PLEK
SAP130
CERS6
PPIG
TTN
NIF3L1
ALS2
CYP27A1
DNPEP
TM4SF20
INPP5D
FRG1BP
BPIFB2
CHD6
PTPRT
CDH22
RNF114
RAB22A
PHACTR3
DOP1B
CABIN1
ASCC2
PIM3
59

CADD
Score
24.1
28
24
23.4
27.4
26.4
27.9

47
6
6
24
24
24
6
6
6
25
24
47
47
24
6
6
3
3
13
7
47
3
7
6
1
1
1
1
7
6
24
6

dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
recessive
recessive
dominant
dominant
dominant
recessive
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant

8.68e-05
2.83e-05
0.00e+00
1.15e-03
2.80e-03
4.40e-03
7.00e-05
1.60e-03
2.20e-03
2.20e-03
6.00e-04
4.00e-07
1.42e-04
4.80e-03
2.00e-04
1.20e-03
8.60e-03
1.22e-02
4.27e-04
3.47e-04
6.59e-04
9.40e-03
1.13e-04
7.12e-05
2.00e-04
1.00e-03
NA
4.00e-04
4.60e-03
1.00e-03
2.40e-03
1.82e-04

22.4
25
23.4
23.8
23.6
25.7
25.6
22.9
21.8
21.8
22.7
28.8
21.3
25.4
29.4
23
25.3
22.8
22.8
29.3
24.6
23.6
26.6
25.1
26.5
25.8
35
26.1
21.8
25.4
28.8
26.7

Chr:bp_REF/ALT

RefSeq

Gene

Family Inheritance MAF

chr3:8745627_C/G
chr3:33425620_G/A
chr3:38370115_G/T
chr3:47267256_G/A
chr3:69033557_C/G
chr3:98901188_T/C
chr3:101852100_G/C
chr3:111593985_T/C
chr3:112047765_G/A
chr3:124398702_C/T
chr3:126157506_G/A
chr3:133450291_T/A
chr3:134495364_G/A
chr3:148882508_C/T
chr3:184060287_T/C
chr4:957985_G/A
chr4:5708392_G/T
chr4:5973820_G/A
chr4:8374992_G/A
chr4:8604114_G/A
chr4:13627422_T/C
chr4:185662169_G/T
chr4:186613132_A/C
chr5:9050437_T/C
chr5:16481072_C/T
chr5:37226859_G/A
chr5:69117269_G/A
chr5:73857727_G/A

rs116840776
rs61751640
rs137869174
rs115200348
rs1532918
rs186164278
rs149007883
rs34219871
rs185826919
rs145790621
rs1176824663
NA
rs143367808
rs370747287
rs142232052
rs147762522
rs544397395
rs115926780
rs143748739
rs143281934
rs138568321
rs113941304
rs188733415
rs34563995
rs143878016
rs191239995
rs143278272
rs115243197

6
24
24
6
9
6
6
6
24
24
25
13
25
25
7
47
24
47
24
47
47
6
6
13
13
25
25
25

dominant
dominant
dominant
dominant
recessive
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant

1.00e-03
1.60e-03
4.00e-04
4.20e-03
5.69e-02
4.00e-04
1.40e-03
6.00e-04
1.60e-03
4.00e-04
0.00e+00
NA
1.51e-04
1.34e-04
4.00e-04
2.08e-03
1.00e-03
4.60e-03
4.00e-04
6.00e-04
4.00e-04
4.35e-04
4.00e-04
4.00e-03
1.60e-03
2.60e-03
2.00e-04
4.60e-03

chr5:102399556_G/A
chr5:135009372_A/G

rs777289666
rs72800379

6
24

dominant
dominant

2.26e-04 22.2
4.00e-04 21.2

chr5:141934581_A/G
chr5:149896500_T/G
chr5:168227978_A/G
chr5:176584197_A/G
chr6:2890296_G/A
chr6:5545236_A/G
chr6:69701469_TC/T
chr6:117270566_C/A

rs1752213933
rs17711594
rs139130485
rs115353627
rs146773314
rs1405389231
rs749272546
rs147838633

CAV3
UBP1
XYLB
KIF9
TMF1
DCBLD2
NFKBIZ
ZBED2
TMPRSS7
KALRN
ALDH1L1
BFSP2
CEP63
CPA3
HTR3C
TMEM175
EVC2
C4orf50
ACOX3
CPZ
BOD1L1
SORBS2
FAT1
SEMA5A
RETREG1
CPLANE1
SLC30A5
ARHGEF2
8
SLCO6A1
CATSPER
3
DELE1
PDE6A
TENM2
CDHR2
SERPINB9
FARS2
LMBRD1
VGLL2

6
6
24
6
6
24
24
47

dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant

0.00e+00
2.60e-03
1.20e-03
2.60e-03
2.00e-04
1.11e-04
6.06e-04
5.65e-05
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CADD
Score
23.8
22.9
22.6
25.4
27.1
21.9
22.7
22.3
25.5
22.8
27.1
23.3
35
27.5
25
24.6
21.1
26
24.5
23
23
26
21.6
20.3
23.3
25.3
22.7
32

26.6
21
24
25.9
23.1
25.5
25.7
24.5

Chr:bp_REF/ALT

RefSeq

Gene

chr6:138334469_AAGG/
A
chr6:160241533_G/A
chr7:6520620_C/T
chr7:48403703_TAACT
C/T
chr7:74060495_G/C
chr7:103557156_G/A
chr7:122093136_G/A
chr7:138580592_C/G
chr7:138903664_T/C
chr7:141790419_G/A
chr7:151238299_C/T
chr8:10832964_T/G
chr8:17550356_T/C
chr8:22311164_C/T
chr8:26507831_A/G
chr8:66128364_C/T
chr8:122952672_G/A
chr8:132637987_G/A
chr8:141189029_C/T
chr8:141490215_G/A
chr8:144264990_G/A
chr9:2718977_G/A
chr9:12694274_G/A
chr9:21304892_C/G
chr9:83623196_G/C
chr9:110406310_T/C
chr9:119167448_G/A
chr9:120605525_T/A
chr9:122628733_G/C
chrX:10134508_G/A
chrX:18996092_C/T
chrX:24826487_G/C
chrX:38106771_C/T
chrX:40636705_G/A
chrX:50607726_T/TC
chrX:53082770_G/C
chrX:70278632_C/G
chrX:108061477_A/G

rs777828045

ARFGEF3 13

dominant

CADD
Score
1.42e-03 20.3

rs747165406
rs994387676
rs770778526

SLC22A2
GRID2IP
ABCA13

6
6
47

dominant
dominant
dominant

9.01e-05 26.2
0.00e+00 27.4
0.00e+00 26.2

rs17855988
rs41275239
rs74882337
rs61751967
rs144488000
rs2234013
rs200380765
rs189959562
rs144865355
rs144253085
rs761565468
rs1461773998
rs142123946
rs1387746525
rs144442267
rs180740682
rs891797581
rs1819809788
rs61752937
rs140371188
rs755653331
rs200661347
rs139063583
rs529484273
rs41316978
rs147157126
rs142899178
rs41548013
rs149869826
rs34678039
rs587780460
rs200235910
rs12857550
rs200756900

ELN
RELN
AASS
TRIM24
KIAA1549
TAS2R5
CHPF2
PINX1
SLC7A2
PIWIL2
PNMA2
TRIM55
ZHX2
DNAAF11
DENND3
MROH5
BOP1
KCNV2
TYRP1
IFNA5
IDNK
SVEP1
BRINP1
MEGF9
OR1B1
WWC3
ADGRG2
POLA1
SYTL5
CXorf38
SHROOM4
TSPYL2
ARR3
VSIG1

13
7
7
6
24
24
7
6
7
7
6
6
6
7
6
1
24
24
6
13
6
25
24
25
25
24
1
24
7
6
24
24
24
6

recessive
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant
dominant

4.01e-02
2.60e-03
2.00e-03
2.20e-03
3.80e-03
3.00e-03
2.00e-04
1.60e-03
1.00e-03
3.20e-03
0.00e+00
0.00e+00
2.00e-03
0.00e+00
1.00e-03
2.80e-03
2.85e-03
0.00e+00
2.00e-03
2.00e-03
5.40e-05
1.32e-04
3.20e-03
0.00e+00
4.40e-03
3.00e-04
3.00e-04
1.60e-03
3.40e-03
4.00e-03
4.54e-03
5.21e-04
2.10e-03
3.00e-04
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Family Inheritance MAF

26.7
22.5
24.9
22.2
22.6
20.9
20.8
24.5
27.8
22.3
22.7
29.3
23.7
23.5
24
24.5
23.5
26.8
23.1
22.7
21.8
22.2
22
23.9
24.7
24.6
22.8
23.8
32
24
23.1
20.9
23.3
23.1

Chr:bp_REF/ALT

RefSeq

Gene

Family Inheritance MAF

chrX:118593238_C/G
chrX:151743779_C/T

rs371818459
rs1396710739

DOCK11
CNGA2

7
25

62

X
dominant

CADD
Score
0.00e+00 22.8
1.21e-05 34

Table 3. VarElect Results for Candidate Genes with Direct Relationship to Olfaction or
Anosmia.
The output of the VarElect tool analysis for genes from the high priority list directly related to
olfaction. Gene is the gene input from the high priority gene list. Description is the description of
the gene symbol. VarElect Score is a PHRED-ranked score indicating how likely the gene is to be
related to the phenotypes (olfaction/anosmia), based on the VarElect algorithm. Average
Disease-Causing Likelihood is a measure by VarElect of how likely disruptions in the gene are to
cause disease. This is largely based on the known relationship of the gene to other
diseases/syndromes.
Gene

CNGA2
DCC
PHYH
OR1B1
OR2W3
OR10G4
OR6Y1
RELN
OR2M2
CPLANE1
PDE6A
ABCA4
PTPRS
DNAAF11
RETREG1
ERCC6
KIAA0586

Description

VarElect Average
Score
DiseaseCausing
Likelihood
Cyclic Nucleotide Gated Channel Subunit Alpha 36.32
0.16
2
DCC Netrin 1 Receptor
22.27
0.37
Phytanoyl-CoA 2-Hydroxylase
16.1
0.33
Olfactory Receptor Family 1 Subfamily B
16.07
0.06
Member 1
Olfactory Receptor Family 2 Subfamily W
14.98
0.02
Member 3
Olfactory Receptor Family 10 Subfamily G
11.81
0.04
Member 4
Olfactory Receptor Family 6 Subfamily Y
11.45
0.09
Member 1
Reelin
10.36
0.53
Olfactory Receptor Family 2 Subfamily M
9.78
0.35
Member 2
Ciliogenesis And Planar Polarity Effector
2.14
0.18
Complex Subunit 1
Phosphodiesterase 6A
2.07
0.16
ATP Binding Cassette Subfamily A Member 4
1.99
0.04
Protein Tyrosine Phosphatase Receptor Type S 1.85
0.69
Dynein Axonemal Assembly Factor 11
1.7
0.21
Reticulophagy Regulator 1
1.56
0.54
ERCC Excision Repair 6, Chromatin Remodeling 1.55
0.04
Factor
KIAA0586
1.4
0.19
63

Gene

Description

TRPM7

Transient Receptor Potential Cation Channel
Subfamily M Member 7
EvC Ciliary Complex Subunit 2
Aryl Hydrocarbon Receptor Interacting Protein
Like 1
Neuron Navigator 2
Chromodomain Helicase DNA Binding Protein 6
Beaded Filament Structural Protein 2
DNA Polymerase Gamma, Catalytic Subunit
Kalirin RhoGEF Kinase
BPI Fold Containing Family B Member 2
Sortilin Related Receptor 1
ATP Binding Cassette Subfamily A Member 13
Pleckstrin
Carboxypeptidase Z
Solute Carrier Family 24 Member 1
Alsin Rho Guanine Nucleotide Exchange Factor
ALS2
Protocadherin 9
Sorbin And SH3 Domain Containing 2
Protein Tyrosine Phosphatase Receptor Type T
Sortilin 1
Zinc Finger BED-Type Containing 2
Synaptotagmin 17
Taste 2 Receptor Member 5
Otogelin
Grid2 Interacting Protein
Semaphorin 5A
Lipase C, Hepatic Type
Multiple EGF Like Domains 9
Transmembrane Serine Protease 7
Pim-3 Proto-Oncogene, Serine/Threonine Kinase
Aldehyde Dehydrogenase 1 Family Member L1
Tubulin Folding Cofactor E
KIAA1549
Elastin
Transmembrane Protein 175
Erythrocyte Membrane Protein Band 4.1

EVC2
AIPL1
NAV2
CHD6
BFSP2
POLG
KALRN
BPIFB2
SORL1
ABCA13
PLEK
CPZ
SLC24A1
ALS2
PCDH9
SORBS2
PTPRT
SORT1
ZBED2
SYT17
TAS2R5
OTOG
GRID2IP
SEMA5A
LIPC
MEGF9
TMPRSS7
PIM3
ALDH1L1
TBCE
KIAA1549
ELN
TMEM175
EPB41

64

VarElect Average
Score
DiseaseCausing
Likelihood
1.32
0.63
1.3
1.07

0.07
0.18

1.05
0.9
0.8
0.75
0.73
0.68
0.61
0.56
0.47
0.44
0.4
0.39

0.50
0.62
0.33
0.56
0.63
0.29
0.46
0.01
0.12
0.11
0.32
0.67

0.39
0.39
0.39
0.38
0.36
0.34
0.3
0.25
0.24
0.24
0.23
0.22
0.22
0.22
0.22
0.22
0.2
0.2
0.2
0.2

0.65
0.65
0.68
0.52
0.51
0.79
0.26
0.00
0.00
0.69
0.41
0.52
0.07
0.70
0.11
0.33
0.01
0.29
0.15
0.48

Gene

Description

MYO3A
MYO1C
KIF1C
CYP27A1

Myosin IIIA
Myosin IC
Kinesin Family Member 1C
Cytochrome P450 Family 27 Subfamily A
Member 1
Titin
Tyrosinase Related Protein 1
Cadherin 22
X-Ray Radiation Resistance Associated 1
Formin Binding Protein 4
Zinc Finger BED-Type Containing 5
DENN Domain Containing 5A
Growth Arrest Specific 2
PNMA Family Member 2
Solute Carrier Family 22 Member 2
NAD Synthetase 1

TTN
TYRP1
CDH22
XRRA1
FNBP4
ZBED5
DENND5A
GAS2
PNMA2
SLC22A2
NADSYN1
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VarElect Average
Score
DiseaseCausing
Likelihood
0.2
0.03
0.2
0.51
0.15
0.63
0.15
0.31
0.15
0.08
0.07
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05

0.00
0.44
0.59
0.15
0.40
0.00
0.54
0.55
0.36
0.69
0.35

Table 4. VarElect Results for Candidate Genes with Indirect Relationship to Olfaction or
Anosmia.
The output of the VarElect tool analysis for genes from the high priority list indirectly related to
olfaction. Gene is the gene input from the high priority candidate gene list. Implicating Genes are
genes directly related to olfaction that are associated in some way with the input gene. VarElect
Score is a PHRED-ranked score indicating how likely the gene is to be related to the phenotypes
(olfaction/anosmia) based on the implicating genes and relationship with the input gene.
Gene
FLG
MAP4K1
LAMA1
TRIM24
FAT1
CDH11
RPS6KA4
ITGA3
ARHGEF11
ATF7IP
ADAM17
MYH8
DCBLD2
MYH10
TLN2
PARD3
CLIP1
MCL1
FBN3
XYLB
IFNA5
TENM2
POLA1
DOCK11
GALE
PTPRQ
NPAP1
ZC3H13
ARHGEF28

VarElect Score
18.68
5.1
4.4
4.01
3.65
3.64
2.86
2.79
2.64
2.29
2.27
2.25
2.23
2.1
2.01
1.97
1.94
1.91
1.91
1.87
1.64
1.61
1.61
1.59
1.56
1.56
1.55
1.52
1.5

Implicating Genes
FGFR1; FGFR2; SEMA3A; FLRT3; SOX10
FGFR1; FGF8; FGF17; DUSP6; AKT1
FGFR1; FLRT3; FGF8; FGF17; GNRH1
FGFR1; FGF8; FGF17; SOX2; DUSP6
FGFR1; CHD7; SEMA3A; AKT1; AXL
FGFR1; SEMA3A; FGF8; GNRH1; FGF17
FGFR1; FGF8; FGF17; GNRH1; SEMA3A
FGFR1; FGF8; FGF17; GNRH1; SEMA3A
FGFR1; FGF8; SEMA3A; GNRH1; FGF17
SPRY4; CCDC141; KITLG; TERT; SP1
FGFR1; DUSP6; TNF; AKT1; FGF8
FGFR1; GNRH1; FGF8; FGF17; SEMA3A
FGFR1; SEMA3A; KISS1R; AKT1; NRP1
FGFR1; FGF8; DUSP6; GNRH1; FGF17
FGFR1; GNRH1; FGF8; FGF17; SEMA3A
FGFR1; FGF8; GNRH1; FGF17; SEMA3A
FGFR1; WDR11; FGF8; GNRH1; FGF17
DUSP6; AKT1; MAPK1; FGFR1; PRKN
FGFR1; CHD7; GNRH1; FGF8; FGF17
CHD7; FGF8; HS6ST1; PNPLA6; ADCY3
FGFR1; FGF8; DUSP6; FGF17; TACR3
TENM1; FLRT3; SHH; LRRK2; IHH
FGFR1; ANOS1; CHD7; PNPLA6; FGF8
CHD7; FGFR1; ANOS1; WDR11; PROKR2
CHD7; FGFR1; HS6ST1; FGF8; FGF17
FGFR1; FGF8; GNRH1; FGF17; SEMA3A
GNRH1; TACR3; KISS1; BBS4; INS
CHD7; WDR11; TCF12; FGFR1; ANOS1
FGFR1; CHD7; ANOS1; WDR11; DCC
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Gene
HTR3C
KCNV2
CABIN1
KCTD3
VGLL2
EIF3J
TNRC6C
PSMB2
LIG1
GGA3
BCAN
ARR3
CCNA1
RIN3
DBX2
CYP4Z1

VarElect Score
1.48
1.46
1.45
1.45
1.45
1.44
1.42
1.42
1.37
1.37
1.32
1.28
1.27
1.21
1.19
1.19

PINX1
DOP1B
FCRL6
SLCO6A1
KASH5
TMF1
ADGRG2
TMPO
ADAMTSL5
ACOX3
ADAMTSL3
NME3

1.18
1.17
1.14
1.09
1.04
1.03
1.02
1.02
0.97
0.97
0.96
0.95

GDPD5
ACBD5
INPP5D
FAM98A
LMBRD1
NOP2
PPIG
BOP1
CERS6
RNF114
CAV3

0.94
0.92
0.89
0.89
0.87
0.87
0.85
0.82
0.81
0.76
0.75

Implicating Genes
FGFR1; FGF8; GNRH1; FGF17; SEMA3A
FGFR1; GNRH1; FGF8; FGF17; SCN9A
FGFR1; CHD7; FGF8; GNRH1; FGF17
FGFR1; GNRH1; FGF8; ANOS1; FGF17
FEZF1; HESX1; PIK3CA; DLL1; PROP1
FGFR1; FGF8; GNRH1; AKT1; FGF17
FGFR1; FGF8; FGF17; SOX2; ANOS1
FGFR1; FGF8; FGF17; DUSP6; SHH
CHD7; FGFR1; FGF8; FGF17; TUBB3
NTRK1; FGFR1; ANOS1; FGF8; FGF17
CHD7; FGFR1; HS6ST1; FGF8; APOE
PROKR2; GNRHR; DUSP6; SHH; KISS1R
FGFR1; CHD7; DUSP6; FGF8; FLRT3
SPRY4; GBA; PARK7; SLC24A4; LRRK2
FEZF1; SOX10; HESX1; GSX2; SOX2
SPRY4; HS6ST1; UGT2A1; ARNT2;
OR10G6
TERT; POLR3B; AKT1; VEGFA; ALB
CHD7; EIF4G1; MON2; ARL13B; CHD4
FGF17; PTPN11; CNGA2; PTPRC; OR1A1
FGF17; CNGA2; OR1A1; OR2H1; OR2A12
DUSP6; RTP2; TNF; DCTN1; HMOX1
WDR11; AKT1; TUBB3; APOE; INS
TACR3; TENM1; OMP; OR5D13; OR2B6
FGFR1; ANOS1; CHD7; WDR11; LRRK2
FGFR1; DCC; FGF8; FGF17; DUSP6
TACR3; PEX7; HS6ST1; PNPLA6; PHYH
FGFR1; FGF8; DCC; FGF17; DUSP6
DUSP6; POLR3B; ADCY3; HS6ST1;
PNPLA6
KISS1; ADCY3; PNPLA6; HS6ST1; ZIC2
FGFR1; ANOS1; WDR11; PROKR2; FGF8
FGFR1; AKT1; DUSP6; PNPLA6; FGF8
WDR11; SOX2; LRRK2; NTRK1; PAX3
FGFR1; FGF8; FGF17; DUSP6; HS6ST1
FEZF1; POLR3B; AKT1; TCF12; APOE
CHD7; SOX2; LRRK2; KIF7; BBS4
DUSP6; SMCHD1; POLR3B; LRRK2; NTRK1
CNGA2; HS6ST1; PNPLA6; AKT1; GBA
WDR11; DUSP6; AKT1; POLR3B; TUBB3
AKT1; SCN9A; ATP13A2; SCN11A; AXL
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Gene
USP6
RTTN
CEP63
NUP58
NDC1
TSFM
TRIM48
NIF3L1
SAP130
CHPF2
KIF9
AASS
CATSPER3
ZNF609
COG7
RAB11FIP2
BOD1L1
CRISPLD2
WSCD1
CPA3
SLC30A5
WIPI1
PHACTR3
CXorf38
RAB22A
COLEC12
KCNE3
ZHX2
ZNHIT2
DNPEP
LYPLAL1
KCNJ18
SLC14A2
DELE1
NFKBIZ
VSIG1
PIWIL2

VarElect Score
0.74
0.73
0.7
0.7
0.7
0.67
0.66
0.65
0.65
0.64
0.62
0.56
0.56
0.55
0.55
0.54
0.53
0.53
0.5
0.5
0.5
0.5
0.5
0.49
0.48
0.47
0.47
0.47
0.45
0.44
0.42
0.42
0.42
0.41
0.41
0.4
0.4

DDX11
SHROOM4

0.4
0.39

Implicating Genes
DUSP6; OR1J2; OR8B2; LRRK2; KIF7
PNPLA6; STIL; GIGYF2; PEX14; ZEB1
KIF7; OFD1; CNGA2; CEP290; TUBB3
FGFR1; DUSP6; HS6ST1; FGF8; FGF17
FGFR1; DUSP6; HS6ST1; FGF8; FGF17
WDR11; FSHB; LRRK2; OFD1; LHB
DUSP6; SOX2; POLR3B; AKT1; CEP290
WDR11; PRKN; ASCL1; SOD1; MFN2
SOX2; POLR3B; TGIF1; POLR2F; TCF12
HS6ST1; PNPLA6; ADCY3; PHYH; ENO2
TUBB3; KIF7; AKT1; TGFB1; MFN2
FLRT3; HS6ST1; PNPLA6; DCC; ADCY3
SCN9A; OR7C1; OR4B1; OR5T3; SCN11A
SOX2; NTRK1; GLI1; AUTS2; NR0B1
INS; ANK1; FSHB; TUBB3; NTRK1
ADCY3; EMX2; LRRK2; KIF7; TUBB3
SOX2; MAPT; SEMA3B; PCM1; CREBBP
DUSP6; CALCA; ENO2; POLR3B; PTCH1
ADCY3; LRRK2; NTRK2; ADCY10; GUCY2D
FSHB; LHB; PAX6; INS; SNCA
FSHB; ATP13A2; AKT1; SLC39A14; ADCY3
MFN2; MITF; TUBB3; APOE; PEX3
DCC; EDN3; SLC6A3; AMH; MAPK1
PAX6; FGFR3; WFS1; HTT; CUX1
AKT1; FSHB; IFT27; ANK1; DNAJC13
DUSP6; TUBB3; POLR3B; APP; AKT1
SEMA3A; ADCY3; PEX7; SCN9A; SCN10A
TCF12; PAX6; SIX3; PTEN; GAS1
POLR3B; SMCHD1; ATF6; FOS; GDNF
BBIP1; CEP290; BBS4; LZTFL1; ENO2
LRRK2; WDR11; MFN2; PTPN11; MC4R
SCN9A; SCN11A; SCN10A; KCNJ11; KCNJ2
PAX2; ADCY3; APOE; TNF; ATP13A2
SCN9A; LRRK2; FOXH1; SCN11A; SCN10A
TCF12; SCN9A; LRRK2; IL1B; AKT1
MFN2; TUBB3; DNAI1; VIM; EPPIN
SLC39A14; POLR3B; OR2C1; POLR2F;
TCF12
POLR3B; KIF7; POLR2F; TUBB3; WFS1
MITF; OR2T34; HTT; NKX2-2; USH1C
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Gene
FARS2
WWC3
TMEM236
SLC7A2
CDK2AP2
C4orf50
SERPINB9
TRIM55
TSPYL2
SYTL5
COLGALT2
ASAP3
TGM7
METTL25B
MIEF2
DENND3
ASCC2
NEBL
BRINP1
UBP1
TM4SF20
KNDC1
SVEP1
CCDC186
ENDOU

VarElect Score
0.39
0.38
0.37
0.37
0.36
0.36
0.35
0.31
0.3
0.3
0.3
0.29
0.29
0.29
0.29
0.29
0.28
0.28
0.27
0.27
0.26
0.25
0.24
0.23
0.23

SPATA20
SCART1
CDHR2
ARFGEF3
LOXHD1
RSRP1
ADPRHL1
FRY
IDNK
C16orf72
TMC5
C2orf16
CZIB

0.21
0.19
0.18
0.16
0.12
0.11
0.11
0.11
0.1
0.1
0.09
0.09
0.05

KIAA0100

0.04

Implicating Genes
FSHB; PARK7; SYP; LHB; SNCA
PTCH1; LRRK2; SOX3; ERBB3; MFN2
SOX3; OR2A5; OR2A42; OR7G1; OR51I2
ADCY3; EDNRB; GNAL; APOE; ATP13A2
MAPK1; PITPNM1; APP; CDK2; MECP2
OR1N1; OR10G4; ZEB1; TAS2R46; NMBR
IL1B; ESR1; ZIC2; AKT1; SNAI2
OR6K2; CRH; ANK1; NKX2-1; TRIM32
APOE; ESR1; TUBB3; ENO2; MAPK1
PAX3; SYP; WFS1; MACROD2; FGF10
OR6K2; NKX2-1; GFAP; NCAM1; APP
KIF7; AKT1; NGFR; MFN2; SNAI2
TGM1; FN1; TGM2; RELA; NFKB1
NTRK1; MEF2D; LMNA
MFN2; SYP; ADCY4; NCS1; CASP6
AKT1; TUBB3; APOE; INS; ANK1
NTRK1; POLR2F; CC2D2A; BAP1; REV3L
FGFR2; PRKN; NF2; NPHP1; MICAL1
AKT1; NF2; GFAP; OPCML; CCND1
GSX2; GLI3; UHRF1BP1; SMARCB1; TBP
BBS1; MYC; TGFB1; MFF; LMNA
MAPT; ZNF423; NTRK2; SP1; MAP2
PAX2; NRXN1; MYC; CRP; CNTNAP2
ERBB3; FRAS1; PTEN; ADCY10; EWSR1
ACE2; VDR; SLC4A4; ENSG00000276390;
RAPGEF3
WFS1; ACE; MYC; GAPDH; ACOX1
OR7M1P; LOXL2; CYP2E1; JPH4; SPRN
DLL1; USH1C; OPCML; MYO7A; IHH
IFT27; ARL6; SLC39A14; GNAS; CRH
TCF4; TP53; SP1; ZEB1; E2F4
APP; SREK1; CLK4; SHMT2; C6orf118
TP53; TBP; FOXO1; NKX2-5; ZNF521
DIS3L2; ADCYAP1; ZEB1; BRCA2; NR5A1
RPGRIP1L; H6PD; G6PD; ZNF180; GNPDA2
XBP1; CREB1; EPAS1
XBP1; SRY; ZEB1; LYPD2; TMC4
XBP1; SOX5; MYC; NFE2L1
ROBO2; CDKN1A; ROBO1; SRP19;
DNAJC17
PSMC4; RUNX1; POU2F1; AHR; ENTR1
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CHAPTER 3 – FROM MUSK TO BODY ODOR: DECODING OLFACTION
THROUGH GENETIC VARIATION
Adapted from: Li B.*, Kamarck M.L.*, Peng Q.*, Lim F-L., Keller A., Smeets M.A.M.,
Mainland J.D., Wang S. From musk to body odor: decoding olfaction through genetic
variation. PLOS Genetics. 2022. 18(2):e1009564.
*these authors contributed equally to this work§

Abstract
The olfactory system combines input from multiple receptor types to represent odor
information, but there are few explicit examples relating olfactory receptor (OR) activity patterns
to odor perception. To uncover these relationships, we performed genome-wide scans on odorperception phenotypes for ten odors in 1003 Han Chinese and validated results for six of these
odors in an ethnically diverse population (n=364). In both populations, consistent with previous
studies, we replicated three previously reported associations (β-ionone/OR5A1,
androstenone/OR7D4, cis-3-hexen-1-ol/OR2J3 LD-band), but not for odors containing aldehydes,
suggesting that olfactory phenotype/genotype studies are robust across populations. Two novel
associations between an OR and odor perception contribute to our understanding of olfactory
coding. First, we found a SNP in OR51B2 that associated with trans-3-methyl-2-hexenoic acid, a
key component of human underarm odor. Second, we found two linked SNPs associated with the
musk Galaxolide in a novel musk receptor, OR4D6, which is also the first OR shown to drive
specific anosmia to a musk compound. This study provides information about coding for human
body odor, and gives us insight into broader mechanisms of olfactory coding, such as how
differential OR activation can converge on a similar percept.
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Introduction
Every individual experiences smell in their own unique way – variation in odor perception can
range from specific anosmias, where an individual completely lacks the ability to perceive a
particular odorous compound, to differences in individual experience of quality, pleasantness,
and/ or intensity of odors (Keller et al., 2012; Charles J. Wysocki & Gilbert, 1989). Comparing this
perceptual variability with genetic variability allows us to identify the role of single odorant
receptors in the perceptual code. Progress in sequencing technology and increased access to
previously genotyped cohorts has enhanced our ability to uncover the genetic components
underlying differences in odor perception.
Olfactory receptors (ORs), the family of proteins responsible for detection of odor
compounds, have a high level of genetic variation relative to other proteins (Hasin-Brumshtein et
al., 2009; Menashe et al., 2003; Olender et al., 2012). Of the 800 olfactory receptor genes, only
about 400 are intact, and, on average, approximately 30% of OR alleles will differ functionally
between two people (Mainland et al., 2013; Olender et al., 2012). Even within the set of intact
genes, a genetic variant can alter function of a single OR and thereby alter perception of an odor.
To date, there are 15 cases where perceptual variability of an odor correlated with a genetic
variant in a receptor that responds to the odor in a cell-based assay (Gisladottir et al., 2020;
Jaeger et al., 2010; Keller et al., 2007; Mainland et al., 2013; McRae et al., 2013, 2012; Menashe
et al., 2007; Trimmer et al., 2019; Wallrabenstein et al., 2013), and 13 further cases with strong
genetic evidence, but no supporting evidence from cell-based assays (Table 1) (Eriksson et al.,
2010, 2012; Gisladottir et al., 2020; Trimmer et al., 2019).
Here, we utilize the same strategy of correlating perceptual and genetic variation, but with
three improvements: 1. Using a larger population to increase power, 2. Conducting genetic
analysis in an understudied population (Han Chinese), as opposed to previous studies that have
been largely conducted in Western (majority Caucasian) populations, and 3. Validating the results
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using an independent population and different methodology, demonstrating the robustness of the
finding.
In this study, we tested a Han Chinese population (n=1003) alongside a smaller
validation cohort (n=364) of a Western population, using odors that have unexplained variability in
perception – Galaxolide, trans-3-methyl-2-hexenoic acid (3M2H), and aldehydes – as well as a
set of odors with previously described associations between perceptual variability and genetic
variants.

Galaxolide: A Musk Compound
The olfactory literature contains a number of examples of compounds with very different
structures but similar odors (Sell, 2006). The perceptual category of musks is perhaps the most
striking example. Compounds in five different musk structural classes – macrocyclic, polycyclic,
nitro, steroid-type, and straight-chain (alicyclic) – all have a similar perceptual quality described
as sweet, warm, and powdery (Rossiter, 1996). The simplest explanation is that all musk
structures activate one receptor or one common subset of receptors that in turn encodes the
perceptual “musk” quality; however, evidence suggests coding of this percept may be more
complex. Individuals can have specific anosmias to one or some, but not all musks (Gilbert &
Kemp, 1996; Whissell-Buechy & Amoore, 1973), suggesting that there is not a single common
coding mechanism.
In this study, we examined Galaxolide, a musk compound with a characterized specific
anosmia (Gilbert & Kemp, 1996; Whissell-Buechy & Amoore, 1973). Galaxolide does not activate
OR5AN1, which was shown to be critical for the perception of other musk compounds in mice
(Sato-Akuhara et al., 2016; Shirasu et al., 2014). The structural variance and common percept
amongst musk compounds allows us to examine different coding mechanisms that are central to
our understanding of how receptor activation relates to odor perception.
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3M2H: A Body Odor Contributor
All mammals use chemosensation as a means of intra-species communication, but the
mechanism of chemosensory communication amongst humans is largely unknown. The growing
evidence for chemical communication between humans suggests that body odor is of particular
importance, as it may be processed differently in the brain than other odors (Lundström & Olsson,
2010) and may influence various social behaviors including kinship recognition, mate selection
(Mahmut & Croy, 2019), and fear priming (Quintana, Nolet, Baus, & Bouchard, 2019). Although
3M2H is only one of ~120 compounds (Labows, Preti, Hoelzle, Leyden, & Kligman, 1979) that
comprise body odor, it is an “impact odor”, meaning that it carries the characteristic scent of body
odor (X. nong Zeng et al., 1991). Furthermore, almost 25% of the population has a specific
anosmia to 3M2H (Baydar et al., 1992; Ferdenzi et al., 2019; X.-N. Zeng et al., 1992; X. nong
Zeng et al., 1991), but this anosmia has not been connected to any olfactory receptor. Identifying
receptors responsible for perception of 3M2H and body odor may have implications for social
communication, malodor prevention, and receptor coding mechanisms for conspecific odors.

Replicating Odor Associations
Previous publications have implicated OR genetic variation in perception of specific
odors. To examine if these associations are robust and consistent across populations, we
measured responses to β-ionone, androstenone (Mainland et al., 2013; Trimmer et al., 2019), cis3-hexen-1-ol (Jaeger et al., 2013, 2010; McRae et al., 2012; Trimmer et al., 2019) and caproic
acid (Trimmer et al., 2019).

Testing Aldehydes in Different Populations
Aldehydes have been shown to vary perceptually across demographic groups such that
self-reported Asian populations rate aldehydes as more intense than Caucasian populations
(Keller et al., 2012), but no specific genetic variants or receptors have been implicated. To assess
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the genetic underpinnings of aldehyde preferences in the Han Chinese population, we tested two
monomolecular aldehydes: decyl aldehyde (Keller et al., 2012) and galbanum oxathiane,
alongside two fragrance mixtures used in home care products: MixA, which has high levels of
aldehydes and is relatively unpopular in Asia, and MixB which has low levels of aldehydes and is
popular in Asia.

Results
To discover genetic variants related to differences in odor perception, we examined how
genetic variation correlated with olfactory phenotypes in two cohorts. The discovery cohort
consisted of 1003 (370 male) Han Chinese participants, and the validation cohort consisted of
357 (161 male) participants collected in New York City. We conducted a principle component
analysis (PCA) and genetic distance analysis of all identified genetic variants to confirm relative
homogeneity/heterogeneity of our discovery and replication populations, respectively. The first
two principal components explained 52% and 23% of the genetic variance. We confirmed that the
discovery population overlapped with the Han Chinese population (CHB) from the 1000 Genomes
Project (Auton et al., 2015) (mean distance to CHB=0.001, CEU=0.07, YRI=0.07), whereas the
validation study population was distributed between different super-populations (mean distance to
CHB=0.05, CEU=0.05, YRI=0.05). The mean distance between any two participants within a
study cohort is smaller in the discovery population (mean distance = 0.007) than in the validation
population (mean distance = 0.047), confirming that the discovery population is more
homogeneous than the validation population (p<2.2x10 -16; Figure 1).
Participants from both cohorts rated intensity and pleasantness of all odors on a 100point scale. The discovery cohort had 10 odors presented at a single concentration. Most
participants performed each olfactory rating task once, but for each odor a set of 100 participants
rated the odor twice throughout the session (test-retest r=0.75). The validation cohort tested 6 of
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the 10 odors in the discovery cohort, some of which were presented at two concentrations
(high/low). Each participant rated all odors twice throughout the session (r=0.69) (Table 2).
In both cohorts, we normalized participant ratings by ranking across odors by intensity
and pleasantness. For the discovery cohort, we performed genome wide association analysis for
20 olfactory phenotypes (to access full results, refer to ‘Data Availability’ section). We identified
novel genetic variants (Figure 2) associated with the intensity rankings of Galaxolide and trans-3methyl-2-hexenoic acid (3M2H) that explain 13.26% and 4.13% of the phenotype variance,
respectively. We can compare this to the maximum expected values provided by heritability
analysis, which estimates 33% (Galaxolide) and 24% (3M2H) of phenotypic variance is
attributable to genetic variation (Table 3). In addition, we replicated published associations for βionone, androstenone, and cis-3-hexen-1-ol (Fig 2). The validation cohort replicated novel
associations identified in the discovery study (Galaxolide, 3M2H) as well as published
associations (β-ionone, androstenone, cis-3-hexen-1-ol). In both cohorts, all the genetic variants
that were significantly associated with pleasantness were also significantly associated with
intensity perception.

OR4D6 variant alleles M263T and S151T are associated with a decrease in Galaxolide intensity
In the discovery study, Galaxolide intensity perception was associated with an OR locus
in chromosome band 11q12.1 (Figure 3a,b). The two peak variants in open reading frames were
both missense single nucleotide polymorphisms (SNPs) in OR4D6: M263T (rs1453541,
p<2.07x10-25) and S151T (rs1453542 p<2.59x10-25) (Figure 3c). The validation study confirmed
that both OR4D6 SNPs correlated with the intensity of the higher of the two tested concentrations
of Galaxolide (M263T p<9.08x10-6, S151T p<1.02x10-5) (Figure 3d). The two SNPs are in high
linkage disequilibrium (LD): the variant allele of S151T is always co-inherited with the variant
allele of M263T (Table 4).
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We examined the associations between Galaxolide and SNPs in other reported musk-activated
ORs, including OR5AN1 (activated by muscone), OR5A2 (activated by all musk compound
families), and OR1A1 (activated by nitro musks) (WO 2019/110630 A1, 2019; Sato-Akuhara et
al., 2016; Shirasu et al., 2014). Of these ORs, only SNPs in OR5AN1 and OR5A2 were
significantly associated with Galaxolide (p=2.98×10-8 and p=4.19×10-17, respectively) (Table 5).
Since both of these SNPs are in strong LD with the novel signal discovered in OR4D6, we
performed further analysis controlling for the top associated SNP in OR4D6, which did not reveal
any signal reaching genome-wide significance. Additionally, only OR4D6 is in the credible set of
the fine mapping analysis (Table 6).
The leading role of OR4D6 is also supported by the meta-analysis of both cohorts where
the two OR4D6 SNPs were the top two associations with Galaxolide intensity (M263T p<3.25x10 29

, S151T p<4.63x10-29). The meta-analysis revealed no significant associations with Galaxolide

pleasantness (Table 7). Based on the evidence from the above analyses we examined the effect
size of the two SNPs in OR4D6 on Galaxolide intensity ratings. The S151T variant explains more
of the phenotypic variance in Galaxolide intensity rankings (13.26% and 7.54% in discovery and
validation cohorts, respectively) than M263T (12.84% and 4.74%). Variant homozygotes (T/T)
ranked intensity lower than reference homozygotes (S/S or M/M) by an average of 33.3% and
17.1% (percentage of full scale) for M263T and 34.5% and 31.4% for S151T, for the discovery
and validation cohorts, respectively (Figure 3c,d).
To search for a mechanistic explanation for the observed associations, we tested high
frequency (>5% frequency in validation cohort) OR haplotypes in high LD in this locus (OR4D6,
OR5A1, OR5AN1, OR5A2; Figure 3b, Table 8). None of the ORs in the associated LD-block, or a
consensus version of OR4D6 across 10 closely related species (Ikegami et al., 2020; Trimmer et
al., 2019) responded to Galaxolide in our assay.
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OR51B2 variant allele L134F is associated with increased 3M2H intensity
In the discovery study, 3M2H intensity perception was associated with an OR cluster in
chromosome band 11p15.4 (Figure 4a,b). The peak variant (rs3898917, p<1.20x10-11) is in a noncoding region in the LD band including OR51B2, and is in an expression quantitative trait locus
(eQTL) affecting OR52A1 (Westra et al., 2013). The validation study confirmed that this eQTL is
correlated with 3M2H intensity ([low] p<7.89x10-5). There are a number of other associated
variants in this LD band, but the only variant in the credible set of the fine mapping analysis
(Table 6) was a nonsynonymous missense SNP, rs10837814 (L134F) in OR51B2 (discovery
p<6.57x10-10, validation p<9.60x10-8) (Figure 4c,d). The meta-analysis confirmed this as the only
significant association with 3M2H intensity ([low] p<7.40x10 -16), and found no further signal for
pleasantness.
Given that the evidence from the meta-analysis and fine mapping analysis pointed to
OR51B2, we examined the effect size of the L134F on 3M2H intensity ranking. The novel variant
explains 4.13% and 9.97% of phenotypic variance in 3M2H intensity rankings in the discovery
and validation cohorts, respectively. Variant homozygotes (F/F) ranked intensity higher than
reference homozygotes (L/L) by an average of 12.8% in the discovery and 20.8% in the validation
(Figure 4c,d)
In order to further search for a mechanistic explanation for the observed associations, we
used a cell-based assay to measure the response of high frequency (>5% frequency in the
validation cohort) OR haplotypes in the associated locus (OR51B2, OR51B4, OR51B5, OR51B6),
as well as in the eQTL-target locus (OR52A1, OR52A4, OR52A5), to 3M2H (Figure 4b, Table 9).
The OR51B2 reference haplotype responded to 3M2H, but the variant haplotype containing
L134F did not (Figure 4e). No other receptors in the OR51B2-associated locus or the eQTL-target
locus responded to 3M2H (Figure 5).
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Replication of previously reported odor phenotype/OR associations
β-ionone/OR5A1
We replicated the association between β-ionone intensity perception and the missense
SNP rs6591536 (D183N) in OR5A1 in the discovery cohort (p<1.84x10-41), the validation cohort
([high] p<7.80x10-39) (Figure 6a,b), and the meta-analysis (p<1.68x10-74). The pleasantness rank
of β-ionone was also associated with D183N in the validation cohort ([high] p<5.53x10 -19) and the
meta-analysis (p<2.25x10-9), but not the discovery cohort (p=0.06). D183N was the top
association with β-ionone, and other significant hits were all within the surrounding LD band
(Table 7).
The variant D183N explains 21.6% and 31.9% of phenotypic variance in β-ionone
intensity rankings in the discovery and validation cohorts, respectively. Variant homozygotes
(N/N) ranked β-ionone intensity lower than reference homozygotes (D/D) by 20% and 38.3% in
the discovery and validation cohort, respectively (Figure 6c,d).

Androstenone/OR7D4
Androstenone perception has been previously associated with the RT/WM haplotype of
OR7D4, which consists of two perfectly linked SNPs (rs61729907 (R88W) and rs5020278
(T133M)). This association was directly replicated in the discovery cohort for intensity (p<
1.07x10-7) and pleasantness (p< 9.56x10-6) ranking of androstenone. The validation cohort
replicated the association for pleasantness (p<0.017), but not intensity (p=0.10). The metaanalysis found associations with RT/WM and both androstenone phenotypes (intensity
p<6.25x10-8; pleasantness p<5.65x10-7). The validation cohort also confirmed the published effect
of another OR7D4 SNP, rs61732668 (P79L), on androstenone perception (intensity p<3.53x10 -4;
pleasantness p<6.88x10-3). This SNP was not sequenced or successfully imputed in the
discovery cohort and therefore could not be examined in the meta-analysis. In the discovery
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cohort, there was one novel association that reached genome-wide significance: rs117391865,
an intronic SNP nearest the gene SYNE1 (p<1.35x10 -8).
The RT/WM variants in OR7D4 predict 2.5% of phenotypic variance in androstenone
intensity rankings in the discovery cohort. WM homozygotes ranked intensity lower than RT
homozygotes by an average 20.6% (Figure 7). The P79L variant in OR7D4 predicts 2.8% of
variance in androstenone intensity in the validation cohort. L homozygotes ranked intensity lower
than P homozygotes by an average 25.6%.
These findings support previous literature: OR7D4 genetic variation has a consistent
effect on androstenone perception, but explains only a small portion of the variance.

Cis-3-hexen-1-ol/OR2J3
The association between cis-3-hexen-1-ol intensity perception and rs28757581 (T113A)
in OR2J3 was nominally replicated in the discovery cohort (p<0.02), but not in the validation
cohort. The meta-analysis results suggest that this is an association at the low (p<0.03), but not
high (p<0.08) concentration. In the meta-analysis, there are a number of associations in the LD
band surrounding OR2J3 (including OR2W1 and OR2J1) at the p<0.05 significance level for
pleasantness of cis-3-hexen-1-ol, and the top signal is rs3129158 in OR2J2 (p<2.3x10 -4). No
associations for cis-3-hexen-1-ol phenotypes reached genome-wide significance. Previous
studies have not consistently demonstrated an association between cis-3-hexen-1-ol and OR2J3.
Here we present evidence that some OR in this LD band may be involved in perception of cis-3hexen-1-ol.

Caproic acid/OR1A1
We could not examine the previously published association between OR1A1 and caproic
acid in the discovery study as this region was not sequenced or successfully imputed. Although
rs17762735 in OR1A1 was associated with intensity in the validation study, the effect of the
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variant on the phenotype was in the opposite direction from the literature (Trimmer et al., 2019).
There were no associations for pleasantness perception of caproic acid with OR1A1. No
associations for caproic acid phenotypes reached genome-wide significance.
There were no associations with aldehyde intensity or pleasantness. No significant
signals were discovered for monomolecular aldehydes (decyl aldehyde and galbanum oxathiane)
or either fragrances, MixA or MixB. The validation study did not examine these compounds.

Derived alleles are ancient and associated with reduced odor intensity
Including the two novel SNPs reported in this study, we examined 29 SNPs that have
been associated with odor perception in the literature (Table 1). From catalogued data by dbSNP,
we extracted information about the evolutionary status of each polymorphism, including the
estimated age of when the mutation occurred, and which allele was derived (mutated) versus
ancestral. In 24 of the 29 SNPs, the age of the derived allele was more than a hundred thousand
years old (112,075-1,491,850 years), predating the population divergence times between East
Asians and Europeans (~55,000 years ago for East Asians and ~41,000 years ago for
Europeans) (Tateno et al., 2014). Several SNPs existed in archaic humans and other non-human
primates (Table 1). Based on the Composite of Multiple Signals (CMS) score, there was no sign
of natural selection for any of the 29 SNPs.
In 21 out of 29 examined cases the derived allele was less sensitive to odors (72.4%;
p<0.01). 13 of these 29 SNPs have been functionally validated by cell assay. Of these 13, there
were 11 cases where the derived allele associated with decreased odor sensitivity (84.6%;
p<0.01).

Discussion
We conducted a genome-wide association study using ten odors and found novel
associations for OR4D6 with the musk odor Galaxolide, and OR51B2 with 3M2H. In addition, we
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replicated previous associations between OR5A1/β-ionone, OR7D4/androstenone, and
OR2J3/cis-3-hexen-1-ol. Furthermore, we have shown that these genotype/phenotype
associations are stable across populations and robust to differences in methods, including odor
concentration and delivery method. Previous genotype/phenotype studies have tended to focus
on variation in olfactory receptors, however differences in olfactory perception could be driven by
genetic variation in other proteins involved in odor signal transduction, such as olfactory axon
guidance molecules, odor-modifying enzymes, or odor transport proteins. Despite our genomewide search, the peak associations were largely located within olfactory receptor loci, suggesting
that differences in olfactory perception caused by genetic factors are frequently driven by
changes in the receptors. It should be noted that the odor perception assessment methods are
different across cohorts, which will inevitably lead to some discrepant results across cohorts.

OR4D6 variation drives differences in perception of Galaxolide, but multiple receptors are
involved in musk perception
Musks are a chemically diverse set of compounds that are defined by their common
perceptual quality; however variation in perception of intensity of different musk odors across
individuals (Gilbert & Kemp, 1996; Whissell-Buechy & Amoore, 1973) suggests several receptors
or groups of receptors may have a contributing role. The musk family, therefore, provides us with
an opportunity to study the convergence of perceptual features of odors through differential
receptor activation in the olfactory code. Prior to our study, there were four human olfactory
receptors that responded to musks in cell culture (WO 2019/110630 A1, 2019; Sato-Akuhara et
al., 2016; Shirasu et al., 2014), but their influence on olfactory perception is unknown. Here we
identified a fifth musk receptor, OR4D6, where genetic variation associated with differences in
perception of the polycyclic musk, Galaxolide. This is the first behavioral evidence that any
human olfactory receptor plays a role in musk perception.
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Other receptors that may be involved in musk perception have shown specificity for a
particular musk or musk chemical family. Mice with a genetically deleted Olfr1440 (MOR215-1)
were unable to find muscone in an odor-finding task (Sato-Akuhara et al., 2016), suggesting that
the receptor is necessary for detection of the polycyclic musk muscone. The human ortholog of
Olfr1440, OR5AN1, has relatively high affinity for several macrocyclic and nitro musk compounds
in a heterologous cell-based assay (Sato-Akuhara et al., 2016; Shirasu et al., 2014). Screening
with this cell-based assay uncovered two other putative human musk receptors, OR1A1 and
OR2J3 (Sato-Akuhara et al., 2016), which respond only to nitro musks, but not Galaxolide or
other polycyclic musks. There is also recent evidence for a broadly tuned musk receptor, OR5A2,
which is activated by musks from all four tested structural classes in vitro (WO 2019/110630 A1,
2019). Together, the existence of musk-specific or musk-family specific, as well as broadly tuned
musk receptors suggests that musks activate separate, but potentially overlapping, sets of
receptors.
Here, we have identified the first case where genetic variation in a receptor is associated
with musk perception in humans. Although OR4D6 is the top association with the Galaxolide
intensity phenotype, it is in high linkage disequilibrium with two previously identified musk
receptors: OR5AN1, and OR5A2. Due to solubility issues with Galaxolide in our cell-based assay,
we were unable to provide functional evidence for OR4D6; however, several pieces of evidence
support the idea that genetic changes in OR4D6 are driving the phenotypic difference in
Galaxolide intensity: 1. In both cohorts OR4D6 is a stronger predictor of Galaxolide intensity than
OR5A2 and OR5AN1, which are not significantly associated with the phenotype after controlling
for the top variant, and 2. With few exceptions, participants homozygous for the OR4D6 variant
are unable to smell Galaxolide (Figure 8).
An interesting finding is that Galaxolide-associated rs1453541 and β-ionone-associated
rs6591536 are in LD (R2 = 0.72) as they are only 14kb apart. The SNP rs6591536 was
functionally validated to be the causal variant affecting the perception of β-ionone (Jaeger et al.,
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2013). However, it is unlikely to be the causal variant affecting the perception of Galaxolide for
the following reasons: 1) Fine-mapping using PAINTOR found the 99% credible set only contain
SNPs rs1453541 and rs1453542, with the posterior probability of 58% and 42%, respectively
(Table 6). The probability of rs6591536 being the causal variant is close to zero. 2) We have
performed cell-based assay on a number of SNPs, including rs6591536, but found no significant
response. 3) If rs6591536 was indeed the causal SNP for the perception of Galaxolide, one would
expect the two phenotypes (perception of Galaxolide and β-ionone) should be correlated to some
extent, but this is not the case (ρ=-0.01, Pearson’s correlation).
OR4D6 is a strong candidate for the mechanism underlying specific anosmia to
Galaxolide, suggesting that it is possible for a single receptor to represent the musk percept. We
do not know if OR4D6 contributes to perception of other musk compounds, but given the in vitro
evidence for other musk receptors and behavioral data that suggest those with Galaxolide
anosmia are still able to smell other musk compounds (Gilbert & Kemp, 1996; Whissell-Buechy &
Amoore, 1973), it is unlikely to be solely responsible for the perception of the musk quality
percept. OR4D6, OR5AN1, and OR5A2 are prime targets for future work on musks, which can
lead more broadly to understanding how activation of different combinations of receptors results
in highly similar percepts.

OR51B2 variation drives differences in the perception of human body odor component 3M2H
Trans-3-methyl-2-hexenoic acid (3M2H) has been described as the ‘impact odor’ for body
odor arising from the underarms, meaning that it is a highly abundant volatile compound and its
quality as a monomolecular odorant is the same as the characteristic quality of body odor (X.
nong Zeng et al., 1991). Specific anosmia to 3M2H has been reported in several studies with
rates ranging from 21-25% of the population (Baydar et al., 1992; Ferdenzi et al., 2019; X. nong
Zeng et al., 1991). Based on its key role in body odor character, it is likely that anosmia to 3M2H
alters body odor perception, although it does not eliminate the ability to smell body odor, as there
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are other reported volatile compounds present in underarm odor (Baydar et al., 1992; Natsch,
Derrer, Flachsmann, & Schmid, 2006; X. nong Zeng et al., 1991).
Here we found that OR51B2 was associated with 3M2H intensity, and responded to
3M2H in a functional assay. Although the OR51B2 haplotype containing the L134F variant is
associated with a higher intensity of 3M2H, it did not respond to 3M2H in a functional assay, This
is surprising, as the more functional variant is typically associated with a higher perceived
intensity. One possibility is that the in vitro assay does not perfectly replicate the environment of
the OSN—the assay has previously failed to provide direct support for genetic associations
(Trimmer et al., 2019). Despite this, the consistent functional response of the reference OR51B2
to 3M2H alongside the validated genetic evidence still strongly suggests that OR51B2 drives
differences in perception of 3M2H intensity. This finding suggests that OR51B2 genotype will
impact the perception of body odor. OR51B2 could be a target for future studies interested in
malodor blocking, or discovering the mechanisms underlying social communication from body
odor. It is worth noting that the distribution of 3M2H intensity was different among the discovery
and validation cohorts, which may be contributed by many factors, such as different
concentrations of odors, different methods for delivering the odors, and different allele frequency
of OR51B2.

Associations between OR5A1/β-ionone, OR7D4/androstenone, and OR2J3/cis-3-hexen-1-ol are
replicated in an East Asian population
In the East Asian discovery cohort, we replicated previous phenotype/genotype
associations between OR5A1/β-ionone, OR7D4/androstenone, and OR2J3/cis-3-hexen-1-ol, but
failed to replicate the OR1A1/caproic acid association. The N183D OR5A1 variant has now been
associated with decreased intensity perception of β-ionone in several studies, as well as verified
in a cell-based assay (Jaeger et al., 2013; McRae et al., 2013). In both the discovery and the
validation cohorts, the β-ionone intensity phenotype had the highest overall effect size, showing
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this association is not only robust to differences in methods, but has also been replicated across
multiple populations.
In the discovery cohort, we replicate the association between RT/WM haplotypes of
OR7D4 and androstenone perception (Keller et al., 2007), that has been replicated in two other
populations (Knaapila et al., 2012b; Lunde et al., 2012). Although the validation study did not
replicate the association with androstenone intensity and RT/WM, it did replicate the association
with androstenone pleasantness, as well as the previously discovered association between P79L
in OR7D4 and androstenone perception (Keller et al., 2007). The lack of signal for intensity
perception and RT/WM in the validation study could be due to differences in odor delivery method
or concentration of the odor, but is more likely due to lack of power in the smaller validation
cohort given that this association was replicated in the meta-analysis. Overall, the evidence here
continues to support the role of OR7D4 in androstenone perception.
Here we nominally replicated the association between cis-3-hexen-1-ol and OR2J3
(McRae et al., 2012). The smaller signal here is not surprising, as this association has failed to
replicate in two other studies (McRae et al., 2013; Trimmer et al., 2019). The original discovery of
this association measured the detection threshold of cis-3-hexen-1-ol, while the two studies that
failed to replicate the original association measured intensity rankings. Since the set of receptors
that associate with variation in olfactory perception differs across concentrations (Trimmer et al.,
2019), this could explain why the cis-3-hexen-1-ol/OR2J3 association failed to replicate
previously and only has a small signal here. It is important to acknowledge that for all of our
genetic associations, our predictive power is limited by the quality of our participant data, as
measured by within-subject test-retest correlation. While it may be possible in future studies to
improve test-retest by conducting additional training of participants, the overall test-retest
correlation in our study is on the high end of the subject reliability range compared to the larger
field of olfactory psychophysics. This may be influenced, in part, by our study design, which
focused on a set of odors known to have high phenotypic variability.
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A previous study found an association between OR1A1 and caproic acid (Trimmer et al.,
2019). This failed to replicate in the validation study, and had no direct replication provided from
the discovery study. The discovery study did have data on variants in the locus surrounding
OR1A1 that had an association signal with caproic acid p<0.05. The role of OR1A1, or perhaps
another OR in this region, in the perception of caproic acid is still unclear.
The majority of previous odor association studies have been conducted in heterogeneous
and majority-European populations, leaving a fundamental gap in knowledge of the wider
relevance of these associations to different populations, such as the East Asian population
examined here. We found that associations tend to replicate across different populations.
Summarizing the variants that alter odor perception, including those reported in past literatures,
our analysis of evolutionary age found 25 of 27 variants predated the population divergence
between East Asians and Europeans (~55,000 years ago for East Asians and ~41,000 years ago
for Europeans) (Tateno et al., 2014). These variants are generally present in both populations at
relatively high frequencies. On the other hand, the two more recently derived variants (S95P in
TAAR5 and A67V in OR1C1) have very low minor allele frequencies in both East Asian and
European populations, suggesting population specific variants that alter odor perception are rare.

Variation in the perception of aldehydes does not associate with olfactory receptors
A study in a large non-homogenous population from New York, NY, tested perceptual
differences of 15 fragrances between self-reported demographic groups. Of all the odors tested,
the largest difference found was in aldehydes, and all three tested aldehydes (decyl aldehyde,
nonyl aldehyde, and undecanal) were significantly different, such that the Asian population
perceived aldehydes to be more intense than the Caucasian population (Keller et al., 2012). The
follow-up study pursuing the genetic underpinnings of these differences did not identify any
associated ORs (Trimmer et al., 2019), and even here, in a larger cohort with a genome-wide
search, there were no associations.
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The lack of genetic evidence here may also be due to the involvement of multiple ORs,
reducing our power to detect specific associations; or the perceptual variation may be due to
cultural, social, or other factors that are not genetic in nature. The more recent evolutionary age
of population-specific variants may play a role, as this these types of odor analyses have
discovered mostly ancient variants, with only two odor-associated SNPs that appeared after the
East Asian and European population divergences. This suggests that increasing population size,
regardless of diversity, may be necessary to discover more recently derived SNPs with lower
minor allele frequency.

Degeneration of olfactory receptor gene repertoires in primates
Compared to many non-primate mammalian species, primates have fewer intact olfactory
receptor genes both in absolute number and by percentage (Matsui et al., 2010). While previous
analyses have been restricted to pseudogenes, recent analyses of the functional consequences
of missense mutations allow for a more detailed examination. We found that in 72% of reported
OR gene/olfactory phenotype associations reported in the literature (85% with functional
validation), derived alleles predicted lower perceived intensity than ancestral alleles. While this
study was not designed to directly address this hypothesis and may suffer from selection bias,
these data support the hypothesis that the primate olfactory gene repertoire has degenerated
over time. The functional implications of this degeneration remain unclear (McGann, 2017;
Shepherd, 2004).

Large genetic databases can be used to understand OR function, a proxy for general protein
function
In the discovery study, we may have the benefit of measuring olfactory phenotypes in a
large, homogenous cohort (Figure 1) where genome-wide genotyping had already been
conducted, giving us the statistical power of a large population without the time or expense. In
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this study, the novel signals do not have much population differences in MAF or effect size (Table
1, Figure 3, Figure 4), suggesting that the large sample size rather than its genetic similarity might
be the more important reason behind the findings. Given the increasing number of open
databases of sequencing data, this method is becoming a more reasonable possibility for easily
testing genotype/phenotype associations.
Olfaction is an excellent use of this new resource because of the ease of understanding
the functional output of genetic variation in the protein. The human olfactory system has both
robust assays to test the behavioral output of these proteins (psychophysics/rating odors) (Keller
et al., 2007; Mainland et al., 2013; Trimmer et al., 2019) and an established method for directly
testing protein function in cells (heterologous cell-based assay) (Trimmer et al., 2014; Zhuang &
Matsunami, 2007). Genetic variation provides a strong tool for exploring olfactory coding and
sheds light on how complex systems integrate information from variable sensors.

Materials and Methods
Study cohorts and participants
The discovery cohort comprised 1003 participants between the ages of 18 and 55, from a
Han Chinese population collected in Tangshan, China. The research was conducted under
approval of the Ethics Committee of Chinese Academy of Sciences (Shanghai, China).
The validation cohort comprised 364 participants between the ages 18-50, from a diverse
population collected in New York, New York, USA. Psychophysics experiments were conducted
under approval from the IRB at Rockefeller University (New York, NY). Written formal consent
was obtained in both cohorts.
Both cohorts excluded participants with medical conditions that affect the sense of smell,
specifically: smoking, recreational drug use, brain surgery or head trauma that required
hospitalization, chronic nasal issues (allergic, tumoral, infectious or inflammatory disease), history
of endoscopic nasal or sinus surgery, any neurodegenerative disease, any upper respiratory
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infection that altered the sense of smell and/or taste for more than 1 month, cervicalgia or other
neck diseases, history of radiation or chemotherapy, alcoholism, current sinus or upper
respiratory infection, seasonal allergic rhinitis or acute rhinosinusitis, and use of medications that
interfere with the sense of smell.

Odor delivery
Discovery cohort participants were tested using felt-tip pens (100.2 mm length, diameter
7.7 mm; ETRA, Königsbach-Stein, Germany) containing an absorbent material loaded with 1 mL
of liquid odor. Each pen was used for no more than 50 participants before being discarded. After
preparation, individual sticks were used within 2 months.
Validation cohort participants smelled 20 ml amber glass vials filled with 1mL of odor. The
vials were presented in a double-blind manner, labeled only with barcodes, to prevent
experimenter bias.

Phenotype ratings
Discovery cohort participants smelled 11 odors (10 unique and one repeat) and verbally
rated the intensity and pleasantness on a 100-point scale. For each odor, a unique set of 100
participants rated the stimulus twice so we could measure the test-retest reliability.
Validation cohort participants also smelled each stimulus and rated intensity and
pleasantness on a 100-point computerized sliding scale. The participants smelled 46 odors at one
concentration, 26 odors at two concentrations, three odors at five concentrations, and three
solvents for a total of 90 stimuli, ten of which are reported here (six odors: four at low and high
concentration and two at high concentration only). Participants smelled stimuli in the same order
to facilitate comparisons across participants, and every stimulus was presented twice.
In both cohorts, in order to normalize for scale usage across raters, intensity and
pleasantness ratings for each participant were ranked from 1 to 10, or 1 to 90, such that the
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odorant with the lowest rated intensity was ranked at 1, and the odorant with the highest intensity
was ranked 10 or 90, depending on the total number of stimuli (Keller & Vosshall, 2004) (Figure
9). The change in ranking metric was calculated as a percentage of the number of ranks changed
over the total number of ranks in the scale (10 or 90), in order to directly compare changes
between the cohorts.
To measure the within-subject reliability of ratings, we calculated the Pearson’s
correlation between duplicate stimuli. Due to methodological constraints of collecting duplicate
participant ratings in the discovery cohort, we conducted this analysis with the raw participant
data, prior to ranking, In the validation cohort, 4 participants were removed due to poor
performance (test-retest correlation <= 0). Individual performance could not be examined in the
discovery cohort, as only one stimulus was repeated for each participant.

Odor concentration and preparation
The discovery cohort included 8 monomolecular odorants (androstenone, β-ionone,
caproic acid, cis-3-hexen-1-ol, Galaxolide, trans-3-methyl-2-hexenoic acid (3M2H), decyl
aldehyde, and galbanum oxathiane) and 2 odor mixtures (MixA and MixB) all prepared by
Unilever. We used isointense concentrations of the ten odors that were diluted in either propylene
glycol or MCT (medium chain triglycerides) (Table 2). To determine the concentration, we utilized
a panel of 14 experts from a sensory flavor panel trained by Unilever. These panelists rated
intensity of ten odorants at three different concentrations (except 3M2H and androstenone which
were rated at 2 concentrations) that were pre-selected to cover a range from weak to strong.
Panelists rated intensity on a scale from 0-15, using a range of concentrations of citric acid for
reference. Ratings were significantly different between all concentrations of odors, except for
androstenone, for which we chose the higher concentration. For each odor, we chose the
concentration that was closest to an intensity of 7, with the exception of two odors (caproic acid
and MixA) for which an original concentration did not result in a rating near 7. For these odors, we
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extrapolated the concentration that would result in an intensity rating of 7 from the other intensity
ratings.
The validation cohort includes data from the following six odors: androstenone, β-ionone,
cis-3-hexen-1-ol, caproic acid, Galaxolide, and 3M2H. The aldehydes and fragrances were not
measured in the validation study. High and low concentrations of odors were intensity-matched to
1/1,000 and 1/10,000 dilutions of 1-butanol, as determined by rankings from a panel of 13
individuals. Odors were presented at both concentrations, except for androstenone and caproic
acid, which were given at concentrations based on previous studies (Keller et al., 2007; Trimmer
et al., 2019). Odors were diluted in paraffin oil or propylene glycol (Table 2).
Due to different delivery methods in each cohort, the concentrations of these six
compounds cannot be directly compared to the concentrations in the discovery study (ComettoMuñiz, Cain, & Abraham, 2003; Cometto-Muñiz, Cain, Hiraishi, Abraham, & Gola, 2000).

Genotyping
Discovery Cohort: Genomic DNA was extracted from blood samples using the MagPure
Blood DNA KF Kit. All samples were genotyped using the Illumina Infinium Global Screening
Array that analyzes over 710,000 SNPs. It is a fully custom array designed by WeGene
(https://www.wegene.com/).
Validation Cohort: Genomic DNA (gDNA) was extracted from saliva samples using the
Oragene Discover 2mL kit and protocol. Library prep (using Agilent SureSelect XT2 kit) and
targeted sequencing were performed by CAG sequencing core (Children’s Hospital of
Philadelphia Research Institute, Philadelphia PA). Custom Agilent SureSelect targets were
designed (eLID# 3028991) for 418 ORs and 290 olfactory-related genes, including other odorant
receptors (i.e. TAARs, MS4A) and related enzymes (i.e. CYP). The Illumina HiSeq platform was
used to perform paired-end sequencing with a read length of 2x125 basepairs on 364
participants.
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Variant calling and quality filtering
Discovery Cohort: Sequences were aligned to genome build GRCh37/hg19 and
genotypes were called using Genome Studio v2.0 (Illumina, 2016). To control for genotype
quality, we implemented exclusion criteria using PLINK v1.90b6.9 (Purcell et al., 2007). No
people were removed due to >5% missing data or failure of X-chromosome gender concordance
check. We excluded SNPs that had >2% missing data (14,385 variants removed), a minor allele
frequency (MAF) <1% (251,918 variants removed), or a deviation from Hardy-Weinberg (HW)
equilibrium (p<1x10-5) (Anderson et al., 2010) (1,149 variants removed), leaving 433,485 SNPs
from 1003 individuals for genome wide association analysis. SNP phasing was performed with
Eagle v2.4 (Loh et al., 2016) using 1000G Phase 3 V5 (GRCh37/hg19) EAS as the reference
panel (Auton et al., 2015). We conducted imputation on the 433,485 phased SNPs using
Minimac4, and obtained a total of 45,843,286 variants. We then re-ran genotype quality control
steps and filtered out 54 variants missing >2% genotype data, 27,361 variants with a deviation
from HW equilibrium (p<1x10-5) (Anderson et al., 2010), and 37,772,956 variants due to MAF
threshold (MAF>0.01), leaving 8,042,915 variants for association analysis.
Validation Cohort: Genotypes were called using a pipeline that follows recommended
‘best practices’ by the Broad Institute (Depristo et al., 2011; Van der Auwera et al., 2013), and as
previously reported (Trimmer et al., 2019). Sequences were aligned to GRCh37/hg19 genome
build using BWA (H. Li & Durbin, 2009). Genotype quality and variant calling steps were
performed using Picard Tools (McKenna et al., 2010b; “Picard toolkit,” 2019). SNP phasing was
performed with SHAPEIT V2.r900 (Delaneau, Marchini, & Zagury, 2012), and OR haplotypes
were assembled using a custom R script. Of the original 18,611 variants called, quality control
measures filtered out 1,488 SNPs that were missing genotype data at a frequency >5% or
deviated from Hardy-Weinberg equilibrium (p<1x10-5) (Anderson et al., 2010). An additional
14,078 variants were removed due to minor allele frequency (MAF>0.05), leaving 3,045 variants
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for association analysis. We adjusted for a more stringent MAF cutoff in the validation cohort, as
the sample size of the validation cohort is relatively small compared to the discovery cohort.
Three individuals were excluded due to > 5% missing data, leaving 357 participants remaining for
genotype/phenotype analysis. For one region of the genome (chromosome band 11p15.4) the
discovery study found significant association in a non-coding region. This region was not
sequenced in the validation study, which focused on open reading frame variants, so we imputed
147,613 SNPs in this region (11:79438 to 11:249222325, hg19).

Population structure analysis
We combined the discovery and validation datasets in order to visualize and quantify
differences in the two study populations. We performed principle component analysis (PCA) using
1,018 linkage disequilibrium-pruned (r2<0.2) SNPs from the combined discovery (n=1003),
validation (n=357), and 1000 Genomes Project (phase 3, 271 participants: 97 CHB, 86 CEU, and
88 YRI) datasets (Auton et al., 2015). We calculated centroids for each population using the first
two eigenvectors. The distances between populations were measured by Euclidian distance of
the centroids. The distances within a population were measured by averaging the Euclidian
distance between each point (participant) and the centroid in the population.

Association analysis
Discovery Cohort: To control for population stratification, we identified the top 10 genetic
eigenvectors to use as covariates by performing PCA on 143,988 LD-pruned (r2<0.2) SNPs from
the 1003 participants of the discovery cohort using Plink (v1.90b6.9) (Price, Zaitlen, Reich, &
Patterson, 2010; Purcell et al., 2007). Using PLINK, we performed genome-wide association
analyses of 8,042,915 SNPs against 20 ranked phenotypes (intensity and pleasantness of 10
odors) under an additive linear model including age, sex, and the top ten genetic eigenvectors as
covariates. Associations were significant if they passed the conventional genome-wide
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significance threshold (p<5x10-8) (Adhikari et al., 2019; Mousas et al., 2017). For loci of interest,
we calculated linkage disequilibrium using LocusZoom (Pruim et al., 2011) using the genome
build from hg19/1000 genomes Nov 2014 ANS. We estimated the heritability of each perception
phenotype explained by LD-pruned SNP set (143,988 SNPs with r2<0.2) using GCTA software
(v1.93.0 beta) (Yang et al., 2010; Yang, Lee, Goddard, & Visscher, 2011).
Validation Cohort: To determine the top 10 genetic eigenvectors (Price et al., 2006, 2010)
for the validation study, we conducted PCA on 10,927 LD-pruned (r2<0.05) SNPs with <5%
missing genotypes and in HW equilibrium (p<1e-5) (but without excluding for MAF) from 361
people (including participants later excluded for poor phenotype data) using the R/Bioconductor
package SNPRelate (Zheng et al., 2012).
We performed genetic association analysis using PLINK (v1.90b5) (Purcell et al.,
2007) to test additive linear models for the 3,045 SNPs from quality control steps and the 78,904
SNPs from the imputed region against each of the 20 phenotypes of interest (intensity and
pleasantness of six odors at one or two concentration each; Table 2) with the top ten genetic
eigenvectors as covariates. For significant loci from the discovery study we set alpha=0.05. For
these loci of interest, we calculated linkage disequilibrium using LocusZoom (Pruim et al.,
2011) with the genome build from hg19/1000 genomes Nov 2014 EUR.
Combined Cohorts: We conducted a meta-analysis of the discovery and validation
cohorts with METAL (Willer, Li, & Abecasis, 2010), which combines weighted p-values, weighted
by sample size, across studies while taking into account and direction of effect.

Fine mapping analysis
We conducted the fine-mapping analysis by leveraging functional annotation data
(GenCode.exon.hg19) and LD information in the discovery and replication cohorts (Kichaev et al.,
2014). We assumed a single causal variant at each locus, examined the SNPs within 200kb
upstream and downstream of the top variant, and calculated the posterior probabilities using
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PAINTOR to determine the 99% credible set. The 99% credible set was constructed by 1) ranking
all variants according to their Bayes factor, and 2) including ranked variants until their cumulative
posterior probability of representing the causal variant at the given locus ≥0.99.

Olfactory receptor cloning and haplotypes
To determine functional consequences for the identified SNPs in the olfactory receptors
(ORs) and nearby receptors in high linkage disequilibrium, we tested activation of specific
haplotypes of the associated ORs, as well as nearby ORs in the same LD-band. We have a large
library of variant and reference haplotypes of ORs that we can use for testing differential
response of receptor variants in the cell-based Luciferase assay. To supplement our library, we
ordered and subcloned the variant haplotype of OR51B2 containing L134F, and the OR4D6
consensus sequence, both into the vector pCI-RHO (GenScript). pCI-Rho (Promega) contains the
first 20 amino acids of human rhodopsin (Krautwurst et al., 1998). Using a consensus version of a
receptor can improve surface expression in a heterologous cell-based assay where the original
receptor is not expressed (Ikegami et al., 2020; Trimmer et al., 2019).
We created a consensus sequence for OR4D6 using orthologs found in Homo sapiens,
Gorilla gorilla, Pan paniscus, Pan troglodytes, Pongo abelii, Macaca mulatta, Mandrillus
leucophaeus, Callithrix jacchus, Microcebus murinus, Rattus norvegicus, and Mus musculus. We
aligned the orthologs using the online version of MAFFT version 7 (Katoh & Standley, 2013), and
determined the most common amino acid at each position for the open reading frame of OR4D6.
The consensus amino acid sequence was printed by GenScript and subcloned into the pCI-Rho
vector (Promega).
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Luciferase assay
We used a heterologous cell-based assay to determine the functional changes caused by
different OR haplotypes for our two novel associations, as has been previously described
(Trimmer et al., 2019, 2014; Zhuang & Matsunami, 2007).
Transfection: Using the Dual-Glo Luciferase Assay System (Promega). We transfected
Hana3A cells with our OR of interest, firefly luciferase driven by a cyclic AMP response element
(CRE) promoter, and Renilla luciferase driven by a constitutively active SV40 promoter,
RTP1S63, and M3-R (Y. R. Li & Matsunami, 2011).
Stimulation: Approximately one day after transfection, we stimulated cells by adding the
odor in a 3-fold dilution series in CD293. Each concentration was run in triplicate, including the
empty vector negative control. Stock odors were kept at 1M in DMSO and diluted in CD293 to the
highest applied concentration of 1mM. Four hours after adding odor to cells, we read the
luminescence output using a Synergy 2 plate reader (BioTek). Luciferase values were normalized
by Renilla luciferase to control for transfection efficiency and cell death, and then averaged
across the triplicate readings.
Analysis: The normalized luciferase values were fit to a three-parameter sigmoidal curve
with a fixed slope (slope=1). We considered a receptor to be activated by an odorant if the
response passed three tests: 1) the standard error of the logEC50 was less than one log unit, 2)
The 90% confidence intervals for the top and bottom parameters of the curve did not overlap, and
3) The dose response curve from the OR-transfected cells was significantly different from the
negative control (empty vector), as calculated by the extra sum-of-squares test. Data analysis
was performed using GraphPad Prism (Version 8).

Evolutionary analysis
We accessed the dbSNP database (https://www.ncbi.nlm.nih.gov/snp/) to determine the
derived and ancestral alleles for our two novel SNP associations and 29 SNPs with previously
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reported odor phenotype associations (Eriksson et al., 2010; Gisladottir et al., 2020; Jaeger et al.,
2010; Keller et al., 2007; Mainland et al., 2013; McRae et al., 2013, 2012; Menashe et al., 2007;
Pelchat, Bykowski, Duke, & Reed, 2011; Trimmer et al., 2019). To our knowledge, this included
all previously published associations between a SNP and an olfactory phenotype, exclusive of
haplotype associations where direction of effect from individual SNPs could not be determined.
We estimated the age of derived alleles using a Genealogical Estimation of Variant Age (GEVA)
model (https://human.genome.dating/) (Albers & McVean, 2020). We checked if these mutations
existed in archaic humans (i.e. Neandertal and Denisova) or in other primates using publicly
available sequences (https://genome.ucsc.edu/Neandertal/, http://cdna.eva.mpg.de/denisova/)
(Green et al., 2010) and UCSC database (https://genome.ucsc.edu/).
We also tested whether these SNPs were under positive selection using the Composite
of Multiple Signals (CMS) method (Grossman et al., 2010). This method generates a composite
score based on three distinct signatures of selection: long-range haplotypes, differentiated alleles,
and high frequency derived alleles. To examine the relationship between derived alleles and a
decrease in odor intensity perception, we performed a one sided two-proportions z-test (R version
6.3.1).

Data Availability
The GWAS summary statistics were deposited in the National Omics Data Encyclopedia
(http://www.biosino.org/node/, Project ID: OEP001806). Data usage is in full compliance with the
Regulations on Management of Human Genetic Resources in China.
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Figures

Figure 1. Population Structure Analysis.
The population structure analysis reveals relative homogeneity of the discovery population (tan
plus-sign) compared to the validation population (black x) (p<2.2x10 -16). Shown are the first two
principle components calculated from all variants genotyped in both the discovery and validation
cohorts. Representative populations from the 1000 Genomes Project: Han Chinese in Beijing
(CHB, n=97; red square), Utah residents with Northern and Western European ancestry from the
CEPH collection (CEU, n=86; blue circle), and Yoruba in Ibadan, Nigeria (YRI, n=88; black
triangle) are plotted for context. The discovery population overlapped with the CHB population
(mean distance to CHB=0.001, CEU=0.07, YRI=0.07).
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Figure 2. Top Associations between Genetic Variation and Odor Intensity Perception.
Each row represents the top SNPs associated with the odor intensity phenotype in the discovery
cohort (blue filled circles) and the replication cohort (red open circles). Listed next to each odor is
the nearest gene to the top SNP for each cohort. There were two novel associations that reached
genome-wide significance in the discovery cohort (p<2.5x10 -9, solid blue line):
Galaxolide/rs1453541(M263T) and rs1453542 (S151T) (p<2.1x10 -25, p<2.6x10-25) and
3M2H/rs3898917 (p<1.2x10-11). The discovery study replicated the associations from the
literature (p<0.05, dotted red line) for β-ionone/rs6591536 (D183N) (p<3.3x10 -43),
androstenone/rs61729907 (R88W) and rs5020278 (T133M) (in both cases, p<1.1x10 -7), and cis3-hexen-1-ol/rs28757581 (T113A) (p<0.02). The discovery cohort was unable to impute the
region around OR1A1 for replication of the caproic acid association. Other than β-ionone, no
replication odors had associations that reached genome-wide significance. For this set of
replication odors (β-ionone, androstenone, cis-3-hexen-1-ol, and caproic acid), the association
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shown is the top association from the LD-band surrounding the previously identified SNP. In the
validation cohort (open red circles), we tested associations for the significant SNPs and
surrounding LD-bands (±200kb) from the discovery study and previous literature. There were four
significant associations in the validation study (p<0.05; red dotted line): β-ionone/rs6591536
(D183N) (p<7.8x10-39), Galaxolide/rs591536 and rs7941591 (p<5.8x10 -6), 3M2H/rs10837814
(L143F) (p<9.6x10-8), and androstenone/rs61732668(P79L) (p<3.5x10 -4). The association for
caproic acid/rs17762735 (p<6.9x10-3) is significant, but in the opposite direction predicted by the
previous study.
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Figure 3. Galaxolide Perception is Associated with Variation in Chromosome Band 11q12.1
in Both Cohorts.
A) a Manhattan Plot of associations with the discovery study in blue and validation study in red
(high concentration) and yellow (low concentration). The red line indicates the threshold for
genome-wide significance (p<5x10-8). Inset: QQ plots from the discovery (blue) and validation
([high]=red, [low]=yellow) cohorts (Genomic Lambda: discovery=1.02; validation=0.90) show
appropriate control for inflation due to population structure. B) The regional plot of discovery
study associations indicates both the significance level and the recombination rate at the OR4D6
LD-band. Genetic variation in OR4D6 affects the perceived intensity of Galaxolide in C) the
discovery cohort and D) the validation cohort (high concentration). The x-axis is ordered left-toright with increasing number of variant alleles for the M263T variant, with population frequency of
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M263T indicated below the genotype. The points colored by S151T genotype suggest that in the
validation cohort, S151T is driving the Galaxolide anosmia phenotype exhibited by those
homozygous for the variant (T/T).
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Figure 4. 3M2H Perception is Associated with Variation in Chromosome Band 11p15.4 in
Both Cohorts.
A) a Manhattan Plot of associations with the discovery study in blue and validation study in red
(high concentration) and yellow (low concentration). The red line indicates the threshold for
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genome-wide significance (p<5x10-8). Inset: QQ plots from the discovery (blue) and validation
([high]=red, [low]=yellow) cohorts (Genomic Lambda: discovery study=1.01; validation
study=0.90) show appropriate control for inflation due to population structure. B) Regional plot of
discovery study associations indicating both the significance level and the recombination rate at
the OR51B2/4 LD-band. The variant L134F (rs10837814; OR51B2) was associated with the
perceived intensity of 3M2H in the C) discovery and D) validation (low concentration) cohorts.
The x-axis is ordered left-to-right for increasing number of variant alleles, with population
frequency indicated below the genotype. E) The OR51B2 reference haplotype responds to 3M2H
in a cell-based assay, but the haplotype containing the L134F variant does not. The empty vector
control (Rho) does not respond to 3M2H, nor do other receptors in the same LD-band such as
OR51B4.
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Figure 5. Cell-based Assay Results for 3M2H.
3M2H was analyzed for activity against other receptors in the OR51B2 cluster, and the eQTL
locus, OR52A1 cluster (Table 9). No receptors responded significantly above the vector control
(Rho). Luciferase values were normalized by RL readings and then baselined to zero by
subtracting the response of the no-odor control.
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Figure 6. β-ionone Perception is Associated with Variation in rs6591536 (OR5A1) in Both
Cohorts.
A) a Manhattan Plot of associations with the discovery study in blue and validation study in red
(high concentration) and yellow (low concentration). The red line indicates the threshold for
genome-wide significance (p<5x10-8). Inset: QQ plots from the discovery (blue) and validation
([high]=red, [low]=yellow) cohorts (Genomic Lambda: discovery study=1.00; validation
study=0.94) show appropriate control for inflation due to population structure. B) Regional plot of
discovery study associations indicating both the significance level and the recombination rate at
the OR5A1 LD-band. The previously discovered D183N variant (rs6591536; OR5A1) also
changes perceived intensity of β-ionone in our populations: C) discovery cohort, D) validation
cohort (high concentration). The x-axis is ordered left-to-right for increasing number of variant
alleles, with population frequency indicated below the genotype.
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Figure 7. OR7D4/Androstenone Association.
Intensity perception of androstenone is is associated with the RT/WM haplotype of OR7D4 in the
discovery cohort. Only data from the discovery cohort is shown here. As predicted from the
literature, the WM variant in OR7D4 reduces intensity of androstenone perception.
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Figure 8. OR4D6 Diplotype.
This shows the intensity of Galaxolide against the diplotypes for OR4D6 including the two
significant SNPs M263T and S151T. In the discovery cohort, the higher LD between these two
SNPs does not allow enough resolution to see which SNP is driving the association. In the
replication cohort, where there is lower LD, it appears that the T/T genotype of S151T is driving
the Galaxolide anosmia phenotype.
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Figure 9. Distribution of Odor Phenotypes.
This is the distribution of ranked intensity (a) and pleasantness (b) ratings for odors in the
discovery (blue) and replication (red) studies. A grey box indicates the phenotype was not tested.
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Tables

Table 1. Variant Age and Effect of Derived Allele on Odor Perception.
In a literature review, derived alleles corresponded with decreased sensitivity to odor in 21 out of
29 cases, and 11 out of 13 cases with functional validation. All but two variants predate the
estimated ages of the East Asian and European population divergences.
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Table 2. Concentrations of Odors from the Discovery and Validation Studies.
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Table 3. Heritability of Phenotypes.
Heritability of ranked intensity and ranked pleasantness of 10 odors estimated by GCTA software
using LD-pruned variants (143,988 SNPs with r2<0.2) from the discovery study.
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Table 4. Frequency of Identified SNPs in OR4D6/Galaxolide Association.
Frequency information for the two SNPs in OR4D6, rs1453541 (M263T) and rs1453542 (S151T)
in discovery and validation cohorts. Haplotypes with the T variant from S151T always have the T
variant from M263T.
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Table 5. Galaxolide Association with Previously Identified Musk Receptors.
These are the results from the association analysis between Galaxolide and SNPs of other
reported musk-related ORs in the discovery cohort (n=1003) before controlling for the top
associated variants (SNPs in OR4D6). OR5AN1 and OR5A2 are in the same LD-band as OR4D6
(Figure 2b), meaning variants in these ORs are more likely to be inherited with the SNPs from
OR4D6. After performing an additional analysis controlling for the top associated SNPs in OR4D6
(p-value after controlling for top SNP), we found no additional significant signal.
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Table 6. Fine Mapping Analysis.
Shown here are all SNPs in the 99% credible set from the fine mapping analysis. For each odor
intensity phenotype, we examined SNPs 200kb upstream and downstream from the top
associated SNP. We used PAINTOR to calculate posterior probability based on functional
annotation linkage disequilibrium. In the case of two highly linked SNPs, such as with OR5A1 and
OR4D6, the posterior probabilities sum to 99%.
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Table 7. Meta-Analysis Results.
Shown are all significant (p<5x10-8) associations for the meta-analysis of discovery and validation
cohorts at both concentrations of odor (n=1360). CHR and BP are the Chromosome and base
position location of the variant. RefSeq is the unique identifier for the variant. A1 and A2 are the
two alleles, which do not necessarily align with the reference and variant alleles, but do determine
the ‘Direction’ column. For example, in row one the prediction is that beta-ionone intensity ratings
will decrease (--) with A2 (g) allele compared to A1 (a) allele. P [high] and P [low] are the p values
for the meta-analysis at high and low concentrations of the odor, respectively.
CHR BP

RefSeq

Task

Odor

A1

A2

11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11

rs6591536
rs7941591
rs1453542
rs1453541
rs7941190
rs10896964
rs7947825
rs1453541
rs1453542
rs1453544
rs11605572
rs17591107
rs6591536
rs7941591
rs1453547
rs11605572
rs17591107
rs1453547
rs1453544
rs1453543
rs10837814
rs75898556
rs7941190
rs6591536
rs7941591
rs10896964

Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Intensity
Pleasantness
Pleasantness
Intensity

beta-ionone
beta-ionone
beta-ionone
beta-ionone
beta-ionone
beta-ionone
beta-ionone
Galaxolide
Galaxolide
beta-ionone
beta-ionone
beta-ionone
Galaxolide
Galaxolide
beta-ionone
Galaxolide
Galaxolide
Galaxolide
Galaxolide
beta-ionone
3M2H
beta-ionone
Galaxolide
beta-ionone
beta-ionone
Galaxolide

a
t
c
t
c
a
a
t
c
a
c
t
a
t
a
c
t
a
a
a
a
t
c
a
t
a

g
c
g
c
g
g
g
c
g
g
g
c
g
c
g
g
c
g
g
g
g
g
g
g
c
g

59211188
59211265
59224885
59225221
59132798
59132882
59210550
59225221
59224885
59224608
59210761
59211421
59211188
59211265
59189912
59210761
59211421
59189912
59224608
59224720
5345128
59245593
59132798
59211188
59211265
59132882
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Dire
ction
-++
++
--++
-++
---++
++
-++
++
--++
++
++
++
++
-++
--

P [high] P [low]
1.7e-74
1.7e-74
4.2e-42
3.5e-40
2.5e-35
3.6e-33
4.9e-30
3.3e-29
4.6e-29
5.2e-28
1.0e-27
1.2e-27
9.8e-27
9.8e-27
1.2e-26
8.2e-21
1.1e-20
1.6e-20
2.0e-20
5.6e-16
2.4e-12
3.7e-11
6.6e-10
2.2e-09
2.2e-09
7.5e-09

1.9e-67
1.9e-67
2.5e-38
1.4e-37
4.1e-31
3.5e-29
8.1e-27
1.7e-24
1.2e-22
9.3e-27
6.5e-27
1.2e-26
9.2e-23
9.2e-23
3.8e-25
7.7e-16
3.0e-15
3.9e-15
2.9e-15
1.1e-13
7.4e-16
1.3e-10
4.2e-09
6.8e-07
6.8e-07
1.1e-08

Table 8. OR4D6-Cluster Haplotypes.
Olfactory receptor haplotypes (hg19) tested in the cell-based assay for activation by Galaxolide
(OR4D6 Cluster). The bolded variants are the SNPs associated with change in Galaxolide
perception. OR4D6 2 is a consensus version of OR4D6 across 10 closely related species.

Table 9. OR51B2-Cluster Haplotypes.
Olfactory receptor haplotypes tested in cell assay for activation by 3M2H (OR51B2/4 Cluster).
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CHAPTER 4 – DISCUSSION
Genetics Tools are Effective For Studying Olfaction Directly in Humans
Much of what we know about the peripheral olfactory system stems from research in
animal models of olfaction, suggesting the need for direct evidence in humans (Lane et al., 2020).
Here we have shown that genetic tools are effective for studying human olfaction. Natural
variation in olfactory-related genes alongside a multitude of unique olfactory phenotypes allowed
us to identify genes related to olfaction in two studies with different scopes.
First, by examining individuals with isolated congenital anosmia (ICA) we identified 215
candidate genes for the disorder. Many of the genes with causal links to ICA are likely to be
necessary for the olfactory system, prospectively through neuronal development and migration,
axonal projections, or component of signal transduction and propagation. This candidate list,
therefore, provides a key resource for understanding the peripheral human olfactory system.
Here, we will discuss strategies for uncovering the underlying mechanisms of the ICA candidate
genes, including potential methodological strategies for determining etiology and analyses to
further prioritize the genes in the candidate list.
Second, by examining large populations of normosmic individuals, we identified two novel
associations between olfactory receptors and odor perception phenotypes. The identification of
individual genes that contribute significantly to a specific odor’s perception provides us with clues
for how coding of olfactory information functions in humans. Here we will discuss how machine
learning models can combine with genetic tools to expand our knowledge of human odor coding
beyond single odor/receptor associations.
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Isolated Congenital Anosmia Can Provide Insight into the Human Olfactory
System
Strategies for determining olfactory functions for ICA candidate genes
In our study of ten families with inherited patterns of isolated congenital anosmia, we
have identified 215 candidate genes that could also play a vital role in olfaction. While some of
these identified genes play roles in olfaction that is well understood, most of these have a
relationship to olfaction that is not well characterized, and some have no previously known
olfactory association. We have suggested several different methods of investigation into these
genes to assess whether and how they affect olfactory function. The role of genes involved in
development of neurons, axon guidance, or migration could be examined by first confirming
expression in olfactory epithelium and/or olfactory bulb by searching RNAseq databases and
validating expression in mice through RT-PCR and immunohistochemistry or in situ hybridization.
For genes that are expressed in olfactory tissues, knockdown or knockout animal models
could be evaluated for olfactory morphology and behavioral phenotypes. Morphological analysis
could include gross anatomical comparisons or examination of specific features using
immunohistochemistry for specific markers of targeted neuronal structures. Behavioral tasks to
determine anosmia or hyposmia phenotypes in mice include assessment of neonatal suckling
behavior and odor-finding tasks. Zebrafish provide another viable model due to the highthroughput tools for genome editing combined with assessment of olfactory deficits through odorfinding behavioral assays.
The role of genes involved in transduction pathways but could first be mechanistically
characterized in human cellular models using CRISPR/Cas9 gene editing strategies, which could
target specific gene variants for deleteriousness. Strategies such as calcium imaging, path-clamp
recording, or other various assays could be used to evaluate gene function in these cell models,
before employing strategies with animal models.
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Examination of individuals with ICA can further prioritize candidate genes
There are various way to restrict or rank the list of 215 gene for follow-up assessment,
such as prioritizing genes with loss of function mutations. Another avenue for assessing priority is
by identifying genes with variants occurring in more than one unrelated family, thus providing
multiple lines of evidence for association with congenital anosmia. From our candidate gene list,
there are 4 genes occurring in more than one unrelated family (MYO3A, PLEK, NEBL, TLN2).
To find more genes with multiple lines of evidence we plan to analyze genetic data
collected from 141 individuals with ostensibly isolated congenital anosmia. These participants
were collected using the same methods as the ten families in the congenital anosmia study, but
lack participating family members or are the only individual in their family with anosmia. We will
perform a targeted search in these individuals for rare, deleterious, coding variants that fall within
any of the 215 genes identified from the ten ICA families.
We had previously conducted this type of preliminary analysis with a prior version of a
candidate gene list generated from the ten families. We first selected all rare, deleterious variants
located within the boundaries of the preliminary candidate gene list, and then identified ICA
individuals who had at least one copy of the variant (for genes selected from the dominant
model), or two copies of the variant (for genes selected from the recessive model). We expected
a sparse dataset where only several genes had variants existing in ICA individuals. Instead, we
found that variants within these genes were nearly ubiquitous amongst ICA individuals. At least
one ICA individual had a variant in every gene, and more than half of the ICA individuals had a
variant in several of the genes. This suggests the need for a more stringent set of filtering steps
for our ICA individuals, for whom the selection step by inheritance model is lacking.
Our current candidate list (Chapter 2, Table 2) has many improvements over the
preliminary version, some of which should improve the analysis for individuals with ICA. We have
made modifications to our sequencing preprocessing pipeline to improve variant calling in our
sequencing preprocessing steps, which should rule out more of the low-quality genotype calls.
122

This has had the downstream effect of increasing the number of variants that have minor allele
frequency data. Many of the overly-represented genes in the preliminary analysis had variants
lacking population MAF data, meaning that they may have been miscalled as rare variant. These
errors were largely nominal in our preliminary family analysis due to the inclusion of normosmic
controls. Although we have made improvements resulting in what we propose is a much more
reliable candidate gene list, it is important to consider how the allele frequency can affect our data
in considering future analysis.
One option is to look at only variants for which we have minor allele frequency(MAF)
information. Variants missing allele frequency information fall into three categories: 1) Variants
that have been characterized in other population datasets that we did not use in our analysis. We
could do a search of other population databases, such as gnomAD (Karczewski et al., 2020), to
acquire MAF and ensure they are rare in the general population. 2) Variants that match the
genomic position of known variants in a general population, but with a novel nucleotide
substitution (i.e. known variant A>C, identified variant in our population A>G). A rough scanning
of these variants suggests they are mostly insertion/deletion variants (indels), which are known to
have a higher variant calling error rate than single nucleotide variants (Fang et al., 2014; Wang et
al., 2022). This suggests removing these variants may be appropriate in our dataset, barring
further methods to access the accuracy of these variant calls. 3) Variants for which there is no
prior information in any population. These are either novel variants or they result from errors in
the preprocessing pipeline. Eliminating these variants in this step may result in removal of some
signal, alongside the noise, however, novel variants determined to be high impact or in the
strongest few candidate genes could be later validated using a second type of sequencing
technology.
An alternate, more conservative, solution would be to conduct analysis that selects for
cases where ICA individuals have a direct replication of the variant identified in the candidate list,
rather than any variant within the gene. Here we would expect to see no more than a few
123

individuals with the recurring variant. Cases where we find many (i.e. >15) individuals with the
same variant suggests an issue that could arise from variant calling steps of sequencing
preprocessing, or improper annotation, and could be used as an additional filtering criteria to
refine our candidate gene list.

Decoding Olfaction Through Genetics
The role of individual receptors in olfactory coding
Canonically, olfactory perception is thought to be coded by the combination of receptors
that activate an odor, yet the importance and contribution of individual receptors to a percept is
not well understood. We have identified two instances where a single olfactory receptor (OR)
influences the perception of odor intensity. First, a variant in OR51B2 was associated with
increased perception of a key element of body odor, trans-3-methyl-2-hexenoic acid (3M2H).
Second, two linked variants in OR4D6 predict specific anosmia to Galaxolide, a musk odor.
The perceptual similarity and structural diversity of musk odors is beneficial for understanding
olfactory coding
The olfactory literature contains a number of examples of compounds with very different
structures but very similar odors (Sell, 2006). The perceptual category of musks, of which
Galaxolide is a member, is perhaps the most striking example. Compounds in five very different
structural classes – macrocyclic musks, polycyclic musks, nitro-musks, steroid-type musks, and
straight-chain (alicyclic) musks – all have a similar perceptual quality described as sweet, warm,
and powdery. At the same time, a small structural variation can result in the complete destruction
of the musk odor, for example the common explosive compound trinitrotoluene (TNT), which is
structurally similar to the nitro musk compounds, but does not have a musk odor. There are
several potential explanations for this phenomenon, including: 1) All musk structures activate one
individual receptor or one common subset of receptors that in turn encodes the perceptual “musk”
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quality. It is unlikely that all musks are activating an individual receptor, as individuals can have
specific anosmia to one, but not all musks (Gilbert & Kemp, 1996; Whissell-Buechy & Amoore,
1973). 2) Each structural class of musk may activate different subsets of receptors, but all of
these subsets converge to convey the same perceptual quality. 3) Each musk is encoded
combinatorially, but with a different pattern than other musks, not necessarily activating
overlapping subsets of receptors defined by structural features.
The structural variety converging on a common percept makes musks an appealing
subject for investigation of the combinatorial code. Additionally, musks have an unusual amount
of perceptual variability within a single perceptual category, (considering the high rates of specific
anosmia (Gilbert & Kemp, 1996)), which means that they are good candidates for examination
through genetic association. Finally, there is some evidence that fewer receptors may be
important in the perception of some musk compounds than for an average odor molecule. The
mutation we identified in OR4D6 predicts anosmia to Galaxolide (B. Li et al., 2022), a much larger
effect than is normally observed in genotype/phenotype associations (Eriksson et al., 2010, 2012;
Gisladottir et al., 2020; Jaeger et al., 2010; Keller et al., 2007; B. Li et al., 2022; Mainland et al.,
2013; McRae et al., 2012; Menashe et al., 2007; Trimmer et al., 2019). Additionally, in mice,
disruption of a single receptor (the mouse homolog of OR5AN1) resulted in anosmia to muscone
(Sato-Akuhara et al., 2016; Shirasu et al., 2014). The high instances of specific anosmias to
musks also suggests a smaller subset of activated receptors, as there would be fewer
opportunities for compensation in a combinatorial code. A smaller combinatorial code would given
musk compounds an additional advantage towards the end goal of fully decoding their
perception.
Expanding single receptor/phenotype associations to the combinatorial code
Our current method of associating variants in receptors to odor phenotypes gives us
insight into the role of individual ORs in the olfactory code, but in order to fully understand the
combinatorial code we must expand to analyses that consider genetics of multiple ORs. Simply
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expanding linear associations to account for multiple receptors is ineffective due to low statistical
power and lack of ability to account for interacting factors. Machine learning, on the other hand, is
well equipped to deal with large sets of data with potentially non-linearly interacting terms.
We performed a proof-of-concept analysis using the data from the validation cohort of
Chapter 3, which was taken from a larger dataset that included a total of 540 participants and
intensity rating for several musk compounds, to show that machine learning models can be used
to examine the larger combinatorial code. We built a regularized random forest (RRF) model to
predict intensity ratings for each of five musks compounds using the ORs genetic variants as the
model variables. To avoid overfitting the model, we subset the data into a training set containing
the 2/3 of the 362 subjects with previously published data, and tested the model’s performance
on the remaining 1/3 of the subjects which were not used in building the model. The RRF model
used ~200 of the most important genetic variants to predict each musk intensity rating, and it
reliably outperformed the linear model in cross-validation, suggesting that this method has utility
in creating multi-OR models of perceptual variation.
The RRF model predicted several novel OR interactions that suggest that the coding for
musk compounds may be combinatorial and structurally-based (Figure 1). Two of the macrocyclic
musks studied had an overlapping set of important variables chosen in their intensity prediction
models, whereas musks from the other structural classes exhibited a different pattern of important
variables. This suggests that musks may be coded by structure, but that indeed different patterns
of OR activation are converging on the same percept.
This proof-of-concept analysis suggests that machine learning can be an effective
strategy for examining the combinatorial code on a larger scale than univariate
genotype/phenotype associations. We could further refine parameters of the RRF model, or use
apply other machine learning algorithms to this set of musk data in order to improve predictive
performance. This could be done without risk of overfitting the model, as there are still 178 of the
original 540 participants whose data have not been examined, and would only be tested once a
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model was finalized. Further study could involve examination of the model predictions of
receptor/odor interactions using the heterologous cell assay described in Chapter 3. As the cell
assay described has been shown to have technical difficulties with some musk compounds due to
solubility issues, other methods of validation may be necessary.
One prediction from proof-of-concept model is that if individuals are anosmic to one
musk, they are more likely to have anosmia to other musks from that structural class. The exact
co-occurrence of musk sensitivity by structural class has not been carefully studied, and could be
examined by having a large cohort of individuals rate intensity of numerous musk compounds.
Such a cohort could involve a larger number of musk compounds, and further genetic sequencing
to expand these machine learning models and validate these preliminary findings in a new cohort.
Given the early success of machine learning models in predicting olfactory phenotypes based on
multiple genetic variants, this methodology could be expanded to other odors, to improve our
knowledge of the olfactory combinatorial code beyond one-receptor-one-odor interactions.
The proof-of-concept RRF model described supplied some evidence to support the
prediction that different OR activation patterns can converge onto a single percept. This can
inform further research into peripheral olfactory processing as well as central olfactory coding
(Gottfried, 2006; Gottfried, Winston, & Dolan, 2006; Zelano & Sobel, 2005; Zhou, Lane, Cooper,
Kahnt, & Zelano, 2019).

Conclusion
We have identified genes that enrich our understanding of basic human olfaction and
coding of olfactory information. This research demonstrates that genetics is an effective tool for
studying human olfaction, but is even more powerful when combined with other techniques, such
as animal behavior and machine learning models, which can provide multiple lines of evidence
supporting the roles of various genes in olfaction. Through these proposed next steps, we have
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provided a road map to growing collective knowledge of the relatively uncharted realm of
peripheral olfactory system functioning and information processing.
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Figures

Figure 1. A Proposed Combinatorial Code for Musk Odorants.
The olfactory receptors listed were the top most important variables for predicting perceived musk
odor intensity using a regularized random forest model. The size of the dot represents the relative
importance of the receptor to model, where larger dots are more important. The importance
measure is computed by the percent increase in mean standard error of the model when the
variable (genetic variant in a receptor) is included in the model compared to cases when it is
excluded. The two macrocyclic musks with similar structure (muscone and cyclopentadecanone)
have a more similar pattern of receptor importance to each other than to musks from other
structural chemical groups. The most important variable predicted in intensity perception of
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Galaxolide is OR4D6, which we identified as potentially causing Galaxolide anosmia(B. Li et al.,
2022).
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